Note: Descriptions are shown in the official language in which they were submitted.
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
METHODS AND COMPOSITIONS FOR TARGETING PD-L1
FIELD
[0001] The present application relates to the fields of chemistry,
biochemistry,
molecular biology and medicine. The present disclosure relates to small
interfering RNA
(siRNA) molecules directed to mIZNA transcripts of CD274 to cause
downregulation of
programmed death-ligand I (PD-L1) expression in humans. The siRNA can be
constructed
of unmodified nucleotides or modified nucleotides that exhibit modified
sugars, nucleobases,
linkages, or covalently bound targeting and/or lipophilic moieties. Also
disclosed herein are
pharmaceutical compositions of siRNAs and uses of or methods of using the
siRNAs for the
treatment of PD-LI related diseases including but not limited to liver
diseases, cancer,
hepatocellular carcinoma, viral diseases, or hepatitis B.
BACKGROUND
[00021 The programmed cell death 1 (PD-1) immune checkpoint expressed
on the
surface of activated CD4 and CD8' T cells controls an inhibitory mechanism to
prevent
autoimmunity. Engagement of P1)-1 by programmed death-ligand 1 (PD-L1)
expressed on
the multitude of cell types, including macrophages, dendritic cells, mast
cells as well as non-
heniatopoietic cells, induces T cell exhaustion resulting in reduction or loss
of effector
cytokine production (e.g. 1L-2, TNT-ct, IFN-y) and upregulation of other
inhibitory receptors
and immune checkpoints (e.g. CTLA.-4, LAG-3, and BTLA), or T cell a.poptosis.
High
expression of PD-Li is exhibited by many types of cancers to escape tumor
immune
surveillance and has been associated with poorer prognosis. PD-1-mediated
immunosuppression is also linked to some viral infections, such as hepatitis
B. There is an
ongoing need for PD-1/PD-L1 therapies and improvements thereof for the
treatment of
disease.
SUMMARY
[0003] Embodiments provided herein related to small interfering RNA
(siRNA)
molecules that target to CD274, compositions thereof, and uses thereof for the
treatment,
-1-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
inhibition, amelioration, prevention or slowing of diseases or conditions
associated with PD-
lol dysregu lati on.
[00041 Some
embodiments provided herein relate to small interfering RNAs
(siRNAs) that targets human CD274 mRNA. In some embodiments, the siRNA
comprises a
sense strand and an antisense strand. In some embodiments, the antisense
strand comprises
18 to 21 nucleotides selected from the group consisting of unmodified
nucleotides and
modified nucleosides. In some embodiments, each modified nucleoside contains a
modified
sugar, contains a modified nucleobase or is abasic, or both contains a
modified sugar and
contains a modified nucleobase or is abasic. In some embodiments, each linkage
between the
nucleosides is a phosphorothioate, phosphodiester, phosphorarnidate,
thiophosphoramidate,
methylphosphate, methylphosphonate, boranophosphate, or any combination
thereof. In
some embodiments, the siRNA is at least 85% complementary to a fragment of
human
CD274 mRNA. In some embodiments, the siRNA comprises zero, one, or two
mismatches to
the fragment of human CD274 mRNA. In some embodiments, the mismatches occur at
any
one or more of positions I or 9 through m, wherein m is the total number of
nucleotides in
the antisense strand. In some embodiments, the mismatches do not occur at a
seed region of
the siRNA, In some embodiments, the seed region is at positions 2-8. In some
embodiments,
the siRNA has a sequence as set forth in any one of SEQ NOs:
2-380. In some
embodiments, the siRNA has 18 nucleotides, In some embodiments, the siRNA has
19
nucleotides, in some embodiments, the siRNA. has 20 nucleotides. In some
embodiments, the
siRNA has 21 nucleotides, In some embodiments, the siRNA. includes a 2-
nucleotide
overhang. In some embodiments, the 2-nucleotide overhang is non-complementary
to the
CD274 mRNA. In some embodiments, the modified sugar is selected from the group
consisting of 2'-0Me, 2'-F, 2'-M0E, 2'-araf, 2'-0Et, 2'-O-alkyl, LNA, scp-
RNA., AmNA,
cEt, ENA., and GNA. In some embodiments, the antisense strand comprises a 5'-
phosphate
group or a 5'-phosphate mimic. In some embodiments, the 5'-phosphate mimic is
a 5'-
vinylphosponate.
[0005] In
some embodiments, the siRNA further includes a targeting and/or
lipophilic moiety. in some embodiments, the targeting moiety is conjugated to
the siRNA at
the 5' end, 3' end, or both. In some embodiments, the targeting moiety is a
fatty acid,
GaINAc, folic acid, cholesterol, tocopherol, or pahnitate. In some
embodiments, the siRNA
-2-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
includes a base selected from the group consisting of adenine, guanine,
cytosine, thymine,
and uracil.
[0006] Some embodiments provided herein relate to pharmaceutical
compositions. In some embodiments, the compositions include an effective
amount of any
siRNA described herein and a pharmaceutically acceptable carrier, diluent,
excipient, or
combination thereof
[0007] Some embodiments provided herein relate to any siRNA as
described
herein or any pharmaceutical composition as described herein for use in
treating a disorder or
disease, such as an infection or a cancer, such as for use in treating
hepatitis B or for use in
treating hepatocellutar carcinoma (HCC). in some embodiments, the siRNA is
used in
combination with surgery, radiation therapy, chemotherapy, targeted therapy,
immunotherapy, hormonal therapy, or antiviral therapy. in some embodiments,
the siRNA
comprises an siRNA against PD-L1 and an siRNA or an antisense oligonucleotide
(ASO)
against hepatitis B virus (HBV).
[0008] Some embodiments provided herein relate to methods for treating
a
disease or disorder in. a subject. In some embodiments, the methods include
administering to
the subject an effective amount of any siRNA as described herein or an
effective amount of
any pharmaceutical composition as described herein. In some embodiments, the
disease or
disorder is an infection or a cancer, such as hepatitis B or hepatocellular
carcinoma, In some
embodiments, the methods further include administering surgery, radiation
therapy,
chemotherapy, targeted therapy, immunotherapy, hormonal therapy, or antiviral
therapy.
[0009] Additional embodiments are described in greater detail below.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] In addition to the features described above, additional features
and
variation.s will be readily apparent from the following descriptions of the
drawings and
exemplary embodiments. It is to be understood that these drawings depict
typical
embodiments, and are not intended to be limiting in scope.
[0011j Figure I depicts fraction of PD-Li mRNA remaining in siRNA
treated
human hepatocellular carcinoma cells (SNU-387 cells) after treatment with
exemplary
modified siRNA sequences provided herein.
-3-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0012] Figure 2 depicts relative gene expression for PD-Li RNA in mouse
liver
72 hours after treatment with exemplary modified siRNA sequences provided
herein.
DETAILED DESCRIPTION
[0013] Unless defined otherwise, all technical and scientific terms
used herein
have the same meaning as is commonly understood by one of ordinary skill in
the art. All
patents, applications, published applications and other publications
referenced herein are
expressly incorporated by reference in their entireties unless stated
otherwise. In the event
that there is a plurality of definitions for a term herein, those in this
section prevail unless
stated otherwise.
[0014] The articles "a" and "an" are used herein to refer to one or to
more than
one (for example, at least one) of the grammatical object of the article. By
way of example,
"an element" means one element or more than one element.
[0015j The terms "about" or "around" as used herein refer to a
quantity, level,
value, number, frequency, percentage, dimension, size, amount, weight or
length that varies
by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference
quantity, level,
value, number, frequency, percentage, dimension, size, amount, weight or
length.
[0016] Throughout this specification, unless the context requires
otherwise, the
words "comprise," "comprises," and "comprising" will be understood to imply
the inclusion
of a stated step or element or group of steps or elements but not the
exclusion of any other
step or element or group of steps or elements.
[0017] By "consisting of' is meant including, and limited to, whatever
follows
the phrase "consisting of" Thus, the phrase "consisting of' indicates that the
listed elements
are required or mandatory, and that no other elements may he present. By
"consisting
essentially of' is meant including any elements listed after the phrase and
limited to other
elements that do not interfere with or contribute to the activity or action
specified in the
disclosure for the listed elements. Thus, the phrase "consisting essentially
of' indicates that
the listed elements are required or mandatory, but that other elements are
optional and may or
may not be present depending upon whether or not they materially affect the
activity or
action of the listed elements.
-4-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[00181 The practice of the present disclosure will employ, unless
indicated
specifically to the contrary, conventional methods of molecular biology and
recombinant
DNA techniques within the skill of the art.
100191 Hepatocellular carcinoma (HCC) is the most common form of liver
cancer. HCC can be caused by a variety of conditions, such as alcohol
consumption,
cirrhosis, and viral infections that cause hepatitis, such as hepatitis B
virus, hepatitis C virus,
and hepatitis D virus. The inflammation, fibrosis, and cirrhosis linked with
these conditions
can induce malignancies in affected liver cells. HCC has relatively poor
prognosis, with a
five-year survival rate of about 30%, depending on if full surgical resection
of the tumor is
possible.
[0020] For early disease, surgical resection is used. However, most HCC
are
identified at later stages because of difficulties in diagnosing. Upon late
stage diagnosis, the
tumors are unresectable, and most patients are given systemic therapies. The
current standard
of care in front line are multi-kinase inhibitors (including, for example,
sorafenib and/or
lenvatinib). Most patients are refractory or relapse from these treatments,
and undergo second
line therapies that have anti-angiogenic agents (including, for example,
Regorafinib,
Caboz.antinib, and/or Ramicirumab) or immune checkpoint inhibitors (including,
for
example, nibolumab and/or pembrolizumab). However, most patients do not
respond to first
and second therapies, and the clinical benefit is poor, with overall survival
not exceeding one
year. In addition, biomarker driven therapies are lacking. Thus, there is a
need to develop
more tolerable and efficacious therapies for the treatment of TICC and related
liver disorders.
[0021] HBV is a partially double-stranded circular DNA of about 3.2
kilobase
(kb) pairs, and is classified into eight genotypes, A to H. The HBV
replication pathway has
been studied in great detail. One part of replication includes the formation
of the covalently
closed circular DNA (cccDNA) form. The presence of the cccDNA gives rise to
the risk of
viral reemergence throughout the life of the host organism. HBV carriers can
transmit the
disease for many years. An estimated 300 million people are living with
hepatitis B virus
infection, and it is estimated that over 750,000 people worldwide die of
hepatitis B each year.
In addition, immunosuppressed individuals or individuals undergoing
chemotherapy are
especially at risk for reactivation of an HBV infection. HBV can be acute
and/or chronic.
-5-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Acute HBV infection can be either asymptomatic or present with symptomatic
acute
hepatitis.
[00221 HBV can be transmitted by blood, semen, and/or another body
fluid. This
can occur through direct blood-to-blood contact, unprotected sex, sharing of
needles, and
from an infected mother to her baby during the delivery process. The HBV
surface antigen
(HBsAg) is most frequently used to screen for the presence of this infection.
Currently
available medications do not cure HBV and/or HDV infection. Rather, the
medications
suppress replication of the virus.
[0023] The hepatitis D virus (HDV) is a DNA virus, also in the
Hepadnaviridae
family of viruses. HDV can propagate only in the presence of HBV. The routes
of
transmission of HDV are similar to those for HBV. Transmission of HDV can
occur either
via simultaneous infection with HBV (coinfection) or in addition to chronic
hepatitis B or
hepatitis B carrier state (superinfection). Both superinfection and
coinfection with HDV
results in more severe complications compared to infection with HBV alone.
These
complications include a greater likelihood of experiencing liver failure in
acute infections
and a rapid progression to liver cirrhosis, with an increased risk of
developing liver cancer in
chronic infections. In combination with hepatitis B, hepatitis D has the
highest fatality rate of
all the hepatitis infections, at 20%. There is currently no cure or vaccine
for hepatitis D.
[0024] Programmed cell death 1, or programmed death 1 (PD-1) is a 268
amino
acid long type I transmembrane protein found as a surface marker on T cells
and other
immune cells. As an immune checkpoint, PD-1 serves to negatively regulate
immune
responses to prevent autoimmune disorder. PD- I protein (NCBI accession number
NP_005009.2) is expressed from the cluster of differentiation 279 (CD279) gene
(NCBI
accession number NG_012110.1) or mRNA transcript (NCBI accession number
NM 005018.3). In some preferred embodiments, PD-I is the human PD-1 protein,
and
CD279 is the human CD279 transcript or gene on chromosome 2. It should be
understood
that a person with ordinary skill in the art would view the terms PD-1 and
CD279 as often
nominally interchangeable when considering the nucleic acid (DNA or RNA) or
corresponding translated protein, or the sequences thereof.
[0025] Programmed cell death-ligand 1, or programmed death-ligand 1 (PD-
L1),
also known as B7 homolog 1 (B7-H1) is 272 amino acid long type I transmembrane
protein
-6-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
found as a surface marker on many different cell types. PD-L1 is a major
ligand of PD-1 and
results in inhibition of T cell cytotoxicity and cytokine production. Cancer
cells such as HCC
cells take advantage of this immune checkpoint by upregulating PD-L1
expression, resulting
in dysfunctional anti-tumor immunity by proximal T cells. Viruses also have
been observed
to modulate the PD-1/PD-L1 pathway to improve infectivity. Hepatitis B virus
has been
shown to upregulate PD-Li in infected hepatocytes, and PD-1 in associated I
cells. PD-Li
protein (NCBI accession number Np...054862.1) is expressed from the cluster of
differentiation 274 (CD274) transcript (NCBI accession number NM_014143.4). In
some
preferred embodiments, PD-Li is the human PD-Ll protein, and CD274 is the
human
CD274 transcript or gene on chromosome 9. It should be understood that a
person with
ordinary skill in the art would view the terms PD-Ll and CD274 as often
nominally
interchangeable when considering the nucleic acid (DNA or RNA) or
corresponding
translated protein, or the sequences thereof.
100261 As
used herein, an "oligonucleotide" refers to a single stranded nucleic
acid molecule that includes unmodified nucleotides, modified nucleotides or a
combination
of modified nucleotides and unmodified nucleotides. In the context of siRNA,
an
oligonucleotide refers to a strand of the siRNA., such as the sense strand (S
strand) or the
antisense strand (AS strand).
[0027] As
used herein, an "unmodified nucleotide" is a nucleotide that has a
deoxyribose sugar or a ribose sugar and a nucleobase selected from adenine,
cytosine,
guanine, thymine and uracil. An unmodified nucleotide can also be considered
to have a
nucleoside selected from cytidine, uridine, 5-methyluridine, guanosine and
adenosine,
deoxycytidine, deoxyuridine, deoxyguanosine, deoxyadenosine, and thymidine.
The
structures of deoxyribose, ribose, adenine, cytosine, guanine, thymine,
uracil, cytidine,
uridine, 5-methy I uridine, guanosine, adenosine,
deoxycytidine, deoxyuri dine,
deoxyguanosine, deoxyadenosine, and thymidine are known to those skilled in
the art.
/CI
100281 As used herein, a
"deoxyribose sugar" has the structure . B
indicates a nucleobase.
-7-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Nr........i B
c 0 /
-1.
[0029] As used herein, a "ribose sugar" has the structure cmi .
B
indicates a nucleobase.
[0030] Relevant positions of the 5-membered sugar ring is provided:
apex
V Base
0
õ.,2-ara-postion
.. . 2'-position .
[00311 As used herein, "modified nucleoside", or "modified nucleotide"
when
involving the 3' or 5' linkage, refers to a nucleoside that (a) includes or
contains a modified
sugar, (b) includes or contains a modified base or is abasic, or (c) both (a)
includes or
contains a modified deoxyribose and (b) includes or contains a modified base
or is abasic. A
modified sugar refers to either a modified deoxyribose sugar or modified
ribose sugar.
[0032] As used herein, the term "modified deoxyribose" refers to a
deoxyribose
sugar that is substituted at one or more positions with. a non-hydrogen
substituent, The
modifications on the deoxy sugar ring can be at any position of the ring,
including at the 2%
carbon. As used herein, the term. "modified ribose sugar" refers to a ribose
sugar that is
substituted at one or more positions with a non-hydrogen substituent. The
modifications on
the deoxyribose sugar or ribose sugar can be at any position of the ring,
including at the 2%
carbon,
[0033] Examples of modified sugars include but are not limited to 2'-
deoxy-2'-
11uoro ribose (2'-F), 2'-deoxy-2'-fluoro-arabinonucioetide (2'-araF),
2%arabinonticleotide
(2'-ara0H), 2'43-methyl ribose (2%0Me), 2%0-(2-methoxyethyl) ribose (2%M0E),
locked
nucleic acid (INA), 2%0-ethyl ribose (2%0Et), 2%0-alkyl, (9-constrained ethyl
(cEt),
ethylene-bridged nucleic acid (ENA), 4'-C-spirocyclopropylene bridged nucleic
acid
(scpBNA), amido-bridged nucleic acid (AmNA), unlocked nucleic acid (UNA), and
glycol
nucleic acid (GNA).
-8-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0034] As used herein, "2'-f" refers to a modified deoxyribose sugar
that has 2'
Base
0
fluorine substitution and has the structure F .
[0035] As used herein, "2'-arar refers to a modified ribose sugar that
has a
-.---\j 1 0 Base
F
fluorine group attached to 2' position, and has the structure
[0036] As used herein, "2'-ara0H" refers to a modified ribose sugar
that has a
----),..i
1 0 Base
OH
hydroxy group attached to 2' position, and has the structure
[0037] As used herein, "2'-0Me" refers to a modified ribose sugar that
has a
Base
0
methyl group attached to the 2' hydroxyl and has the structure 001-13.
[00381 As used herein, "2'-MOE" refers to a modified ribose sugar that
has a 2-
methoxyethyl group attached to the 2' hydroxyl and has the structure
Base
0
OCH2CH2OCH3.
[0039] As used herein, a "locked nucleic acid" or "1-NA" refers to a
modified
ribose sugar that includes a linkage that connects the 2'-position to the 4'-
position of the 5-
-9-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
0
membered ring. Examples of locked nucleic acids include 0 and
Base
0
, and those described in PCT publications WO 2011/052436, WO
2014/046212, and WO 2015/125783, each of which are hereby expressly
incorporated by
reference for the purpose of their disclosure of LNAs.
[0040] As
used herein, "2'-0-Ethyl" refers to a modified ribose sugar that has an
0
Base
ethyl group attached to the 2' hydroxyl and has the structure OCH2CH3,
[0041] As
used herein, "cEt" refers to a modified ribose sugar that includes a
methyl that bridges the 2' hydroxyl and the 4' carbon, and has the structure
Base
0
[0042] As
used herein, "scpBNA." refers to a modified ribose sugar where a
cyciopropane bridges the 2' hydroxyl. and 4' carbon and has the structure
Base
0
-10-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0043] As
used herein, "AmNA" refers to a modified ribose sugar where the 2'
Base
0
0 and 4 carbon are bridged with an amide bond and has the structure NR
[0044] As
used herein, an "unlocked nucleic acid" or "UNA" refers to a modified
nucleotide wherein the bond between the 2'-position and the 3'-position of the
5-membered
=
= Base
0
sugar ring is not present (acyclic ribose), and has the structure OH
[0045] In
each of the structures, the "Base", referring to a nucleobase, can be an
unmodified base, a modified base or absent, such that the nucleotide is
a.basic. When not
indicated, the nucleotide may be an unmodified nucleotide, modified
nucleotide, or abasic,
[0046] A
"modified base" refers to any base other than adenine, cytosine,
guanine, thymine and uracil. For example, a modified base can be a substituted
adenine, a
substituted cytosine, a substituted 5-methylcytosine, a substituted guanine, a
substituted
thy-mine, or a substituted uracil. Alternatively, a modified base can make up
a modified
nucleoside such as a substituted cytidine, a substituted 5-methyl-cytidine, a
substituted
uridine, a substituted 5-methyluridine, a substituted guanosine, a substituted
adenosine, a
substituted deoxycytidine, a substituted 5-methyl-deoxycytidine, a substituted
deoxyuridine,
a substituted deoxyguanosine, a substituted deoxyadenosine, or a substituted
thymidine.
[00471 When a
specific linkage between the nucleotides are not specified, the
linkage may be a phosphodiester or a non-phosphodiester linkage and may be a
linkage
and 2'-5' linkage, such as a phosphorothioate, a methylphosphonate, a
phosphoramidate, a
thiophosphoramidate, a phosphonoacetate, an amide linkage, or a
boranophosphate linkage.
o O.,P
o \O-4
The phosphodiester can have the structure or
-1
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0048] As
used herein, a phosphorothioate is used as understood by those skilled
in the art and refers to a phosphate wherein one oxygen is replaced with a
sulfur. The
0 0
e
s _________________________________________ ` 4
phosphorothioate can have the structure a or Hs \0
[0049] As
used herein, a methylphosphonate is used as understood by those
skilled in the art and refers to a phosphate wherein one oxygen is replaced
with a methyl. The
0
,
H30 01
methylphospbonate can have the structure
[0050! As
used herein, a phosphoramidate is used as understood by those skilled
in the art and refers to a phosphate wherein one oxygen is replaced with an
amide. The
0
0 HN
phosphorami date can have the structure
[0051] As
used herein, a thiophosphoramidate is used as understood by those
skilled in the art and refers to a phosphate wherein one oxygen is replaced
with a sulfur and
one oxygen is replaced with an amide. The thiophosphoramidate can have the
structure
0
eS/
jP\
[0052] As
used herein, a phosphonoacetate is used as understood by those skilled
in the art and refers to a phosphate wherein one oxygen is replaced with a
¨CH2-C,(=0)0- or
6
0 O.
---012-C(-0)0H. The phosphonoacetate can have the structure 00 Or
0 O. /
õ o4\.\..
HO
-12-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0053] As used herein, an amide linkage is used as understood by those
skilled in
.11.11.AP
0 :3'
HN
the art and refers to an amide. The amide linkage can have the structure '
s.,,csys
[0054] As used herein, a boranophosphate is used as understood by those
skilled
in the art and refers to a phosphate, wherein one oxygen is replace with a
boron group. The
0
/
0 /P\
H3B 01-
boranophosphate can have the structure
[0055] In some embodiments, the nucleosides are linked with all
phosphodiester
linkages. In some embodiments, the nucleosides are linked with all
phosphorothioate
linkages, In som.e embodiments, the nucleosides are linked with all
methylphosphonate
linkages. In some embodiments, the nucleosides are linked with all
phosphoramidate
linkages. In some embodiments, the nucleosides are linked with all
thiophosphoramidate
linkages. In some embodiments, the nucleosides are linked with all
phosphonoacetate
linkages. In some embodiments, the nucleosides are linked with all amide
linkages. In some
embodiments, the nucleosides are linked with all boranophosphate linkages. In
some
embodiments, the nucleosides are linked with a combination of phosphodiester
and
phsophorothioate linkages. In some embodiments, the nucleosides are linked
with a
combination of phosphodiester, phosphorothioate, methylphosphonate,
phosphoramidate,
thiophosphoramidate, phosphonoacetate, amide, and boranophosphate linkages,
including
combinations where at least one type of linkage is not present.
[0056] Those skilled in the art understand that when the linkage is a
non-
phosphodiester linkage, the phosphorus can be a chiral center. For example, in
a
phosphorothioate, the phosphorus can be a (R)-stereocenter or a (S)-
stereocenter. In some
embodiments, each phosphorus of a non-phosphodiester linkage can be a (R)-
stereocenter. In
other embodiments, each phosphorus of a non-phosphodiester linkage can be a
(S)-
stereocenter. For example, in an oligonucleotide that has a phosphorothioate
between each
-13-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
nucleotide, each phosphorothioate can be in the (S)-configuration. In still
other embodiments,
the oligonucleotide can include at least one non-phosphodiester linkage,
wherein the
phosphorus can be a (S)-stereocenter, and at least one non-phosphodiester
linkage, wherein
the phosphorus can be a (R)-stereocenter. In some embodiments, a particular
linkage within
an oligonucleotide may be present in a racemic mixture. In some embodiments, a
particular
linkage within an oligonucleotide may be present in an unequal mixture of (R)
and (S)
stereoisomers. For example, a particular linkage may be present where the
ratio between (R)
and (S) stereoisomers is 0%:100%, 10%:90%:, 20%:80%, 30%:70%, 40%:60%,
50%:50%,
60%:40%, 70%:30%, 80%:20%, 90%:10%, 100%:0 A, or any ratio in the range
defined
between any two aforementioned ratios. In some embodiments, a particular
linkage within an
oligonucleotide is enantiomerically pure, (R) enantiomerically pure, or (S)
enantiomerically
pure.
[00571 it is understood that, in any compound described herein having
one or
more chiral centers, if an absolute stereochemistry is not expressly
indicated, then each
center may independently be of (R)-configuration or (S)-configuration or a
mixture thereof.
Thus, the compounds provided herein may be enantiomerically pure,
enantiomerically
enriched, laconic mixture, diastereomerically pure, diastereomerically
enriched, or a
stereoisomeric mixture. Likewise, it is understood that, in any compound
described, all
tautomeric forms are also intended to be included.
[0058] As used herein, the term "small interfering RNA" or "siRNA" has
its
ordinary meaning as understood in ligh.t of the specification, and refers to a
class of double-
stranded RNA molecules, which interferes with the expression of specific genes
having a
nucleotide sequence complementary to the siRNA. siRNAs typically have a well-
defined
structure: a short double-stranded RNA (dsRNA.) with phosphorylated 5' ends
and
hydroxylated 3' ends with two overhanging nucleotides. The Dicer enzyme
catalyzes
production of si.RNA.s from long dsRNA.s and small hairpin RNAs (shRNAs).
Double
stranded siRNA associates with the RNA-inducing silencing complex (RISC), one
strand (the
passenger, or sense strand) is lost, and the remaining strand (the guide
strand, or antisense
strand) cooperates with RIS to bind complementary target RNA. In some
embodiments, the
siRNA disclosed herein may include about 15 to about 35 base pairs, such as
15, 16, 17, 18,
19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 base
pairs in length. In
-14-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
some embodiments, the siRNA antisense strand is complementary to a fragment or
portion of
target mRNA, such as CD274 mRNA, for initiating transcriptional silencing. In
some
embodiments, the siRNA provided herein includes a modification. In some
embodiments,
any of the modifications described herein are applied to the sense strand. In
some
embodiments, any of the modifications described herein are applied to the
antisense strand.
In some embodiments, the modification confers one or more beneficial
characteristics to the
siRNA, such as limiting degradation of the siRNA, improving half-life of the
siRNA,
increasing potency, activity, stability, safety, efficacy, solubility,
permeability, selectivity,
bioavailability, or melting temperature.
[0059j in some embodiments, the antisense strand of the siRNA includes
a 5'-
phosphate. In some embodiments, the antisense strand of the siRNA includes a
5'-phosphate
mimic. The phosphate or phosphate mimic includes 0C- and/or [3- configuration
with respect
to the sugar ring or combinations thereof. The phosphate or phosphate mimics
is a natural
phosphate, phosphorothioate, phosphorodithioate, boranophosphate,
boranothiophosphate,
phosphonate, halogen substituted phosphonates, phosphorami dates,
phosphodiester,
phosphotriester, thiophosphodi ester, thiophosphotriester, diphosphates,
and/or triphosphates.
Suitable phosphate mimics include 5'-phosphonates, such as 5'-
methylenephosphonate (5'-
MP) and 5'-(E)-vinylphosphonate (5'-VP), and 4'-phosphate analogs that are
bound to the
4'-carbon of the sugar moiety (e.g., a ribose or deoxyribose or analog
thereof) of the 5%
terminal nucleotide of an oligonucleotide, such as 4'-oxymethylphosphonate, 4'-
thiornethylphosphonate, or 4'-aminornethylphosphonate, in some embodiments,
the 5'-
phosphate mimic is a 5'-vinylphosphonate.
[0060] The siRNA can be modified with at least one moiety, such as a
targeting
moiety. In some embodiments, the targeting moiety is a lipophilic moiety. In
some
embodiments, the targeting moiety is a long chain fatty acid having a general
structure of
Cf13(CI-12)11(Cfl)mCOOH, wherein n is a whole number ranging from 1 to 30, and
wherein m
is a whole number ranging from 1 to 30. Examples of a targeting moiety
include, but are not
limited to N-acetylgalactosamine (GaINAc, including, for example, a
triantennary-GalNAc,
including, for example, GaINAc3, GaINAc4, GaINAc5, GaNAc6 and/or (ia1NAc7),
folic
acid, cholesterol, tocopherol, vitamin E. or palmitate. Additional examples of
long chain fatty
acids include, but are not limited to, docohexanoic acid, docosanoic acid,
linoleic acid
-15-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
(omega-6), linolenic acid (omega-3), oleic acid, octanoic acid, decanoyl acid,
dodecanoyl
acid, stearic acid, eicosanoic acid, and arachidonic acid. In some
embodiments, the targeting
moiety results in preferential targeting of the siRNA to a certain organ or
tissue, such as the
liver, heart, lung, brain, bone, muscle, kidney, stomach, small intestine,
large intestine, or
pancreas. In some embodiments, a targeting moiety is conjugated to the 5' end
of the siRNA.
In some embodiments, a targeting moiety is conjugated to the 5' phosphate of
the siRNA. In
some embodiments, a targeting moiety is conjugated to the 3' end of the siRNA.
In some
embodiments, a targeting moiety is conjugated to the 3' sugar hydroxyl of the
siRNA. In
some embodiments, a targeting moiety is conjugated to the 5' end and another
targeting
moiety is conjugated to the 3' end of the siRNA. In some embodiments, a second
targeting
moiety can be conjugated to a first targeting moiety. In some embodiments, a
targeting
moiety is attached with a linker. In some embodiments, the linker is a
nucleotide, such as
adenine, guanine, cytosine, thymine, or uracil nucleotides, or non-nucleoside
linkers,
including triethylene glycol (TEG), hexaethylene glycol (HEG), or alkyl amino
linker.
[0061] GalNA.c as used herein has the following structure
\
/
0
I
)
/ 11
siRNA 0
p.-814
\
i10 DH
0 IN
;1-.814 Q
\
o )
wherein R is OH or SH, and wherein n is any integer, in som.e embodiments, the
deoxycytosine nucleotide shown in this structure linking the siRNA to the
GaINAc moiety is
optional, and can be omitted. In some embodiments, n ranges from 0 to 10, such
as 0, 1, 2, 3,
4, 5, 6, 7, 8, 9, or 10. For example, for GaINAc4, n=1; and for GaINAc6, n=2.
However, it is
to be understood that n may equal any integer and may be selected based on the
desired
characteristic of the targeting moiety.
-16-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0062] As used herein, the term "Xmer" refers to an oligonucleotide or
nucleic
acid polymer that is "X" nucleotides long. For example, a 14mer is an
oligonucleotide or
nucleic acid polymer that is 14 nucleotides long, and a 20mer is an
oligonucleotide or nucleic
acid polymer that is 20 nucleotides long. In some embodiments, the "X" refers
to the total
number of nucleotides. In other embodiments, the "X" refers to the number of
nucleotides
involved in binding to the target, while the oligonucleotide or nucleic acid
polymer may have
additional nucleotides or components that are not involved in binding to the
target.
[00631 in some embodiments, at least one siRNA is used to treat liver
disease. In
some embodiments, the liver disease includes but is not limited to liver
cancer, hepatocellular
carcinoma (HCC), cholangiocarcinoma, hepatitis, hepatitis A, hepatitis B,
hepatitis C,
hepatitis D, or any combination thereof. In some embodiments, the at least one
siRNA is
used to silence expression of a gene involved in a liver disease. In some
embodiments, the
gene is CD274. In some embodiments, the at least one siRNA results in at least
10%, 20%,
30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
99%,
or 100% reduction in the disease or symptoms thereof, or in an amount within a
range
defined by any two of the aforementioned values.
[0064] The term "isolated" as used herein refers to material that is
substantially or
essentially free from components that normally accompany it in its native
state. For example,
an "isolated cell," as used herein, includes a cell that has been purified
from. the milieu or
organisms in its naturally occurring state, a cell that has been removed from
a subject or from
a culture, for example, it is not significantly associated with in vivo or in
vitro substances.
[0065] As used herein, the abbreviations for any protective groups and
other
compounds are used, unless indicated otherwise, in accord with their common
usage.
[0066] It is to be understood that where compounds disclosed herein
have unfilled
valencies, then the valencies are to be filled with hydrogen or isotopes
thereof, e.g.,
hydrogen-I (protium) and hydrogen-2 (deuterium).
[0067 it is understood that the compounds described herein can be
labeled
isotopically. Substitution with isotopes such as deuterium may afford certain
therapeutic
advantages resulting from greater metabolic stability, such as, for example,
increased in vivo
half-life or reduced dosage requirements. Each chemical element as represented
in a
compound structure may include any isotope of said element. For example, in a
compound
-17-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
structure a hydrogen atom may be explicitly disclosed or understood to be
present in the
compound. At any position of the compound that a hydrogen atom may be present,
the
hydrogen atom can be any isotope of hydrogen, including but not limited to
hydrogen-1
(protium) and hydrogen-2 (deuterium). Thus, reference herein to a compound
encompasses
all potential isotopic forms unless the context clearly dictates otherwise.
[0068j Where
a range of values is provided, it is understood that the upper and
lower limit, and each intervening value between the upper and lower limit of
the range is
encompassed within the embodiments.
siRNA Synthesis
[00691 Each
of 2'-011/1e, 2'4\40E, and LNA phosphoramidite monomers were
procured from commercially-available sources. All the monomers were dried in
vacuum
desiccator with desiccants (P205, RT 24h). Universal solid supports (CPG)
attached were
obtained from ChemGen.es. The chemicals and solvents for synthesis workflow
were
purchased from VWR/Sigma commercially-available sources and used without any
purification or treatment. Solvent (.Acetonitrile) and solutions (amidite and
activator) were
stored over molecular sieves during synthesis.
[0070] The
control and target oligonucleotide sequences were synthesized on an
Expedite 8909 synthesizer using the standard cycle written by the manufacturer
with
modifications as needed to wait steps and coupling steps. The solid support
was controlled
pore glass and the monomers contained standard protecting groups. Each
chimeric
oligonucleotide was individually synthesized using commercially available 51-0-
(4,4'-
dimethoxylrity1)-3'-0-(2-cyanoethyl-N, N-dii.sopropyl) DNA, 2'-0Me, 2'-MOE and
or INA
phosphoramidite monomers of 6-N-benzoyladenosine (AB, 4-N-acetylcytidine (cm),
2..x.
isob uty rylguanosine (Gil3u), and Uridine (U) or Thymidine (T), according to
standard solid
phase phosphoramidite synthesis protocols. The
2'-0-Me-2,6, diaminop urine
phosphoramidite was purchased from Glen Research. The phosphoramidites were
prepared
as 0.1 M solutions in anhydrous acetonitrile. 5-Ethylthiotetrazole was used as
activator, 3%
Dichloroacetic acid in dichlorometha.ne was used to deiritylate, acetic
anhydride in Tiff and
16% N-methylimidazole in TI-IF were used to cap, and DDTT ((dimethylamino-
methylidene)
amino)-314-1,2,4-dithiazaoline-3-thione was used as the sulfur-transfer agent
for the
-18-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
synthesis of oligoribonucleotide phosphorothioates. An extended coupling of
0.1M solution
of phosphoramidite in CH3CN in the presence of 5-(ethylthio)-111-tetrazole
activator to a
solid bound oligonucleotide followed by extended capping, oxidation and
deprotection to
afford the modified oligonucleotides. The stepwise coupling efficiency of all
modified
phosphoramidites was more than 98.5%.
[00711 Deprotection and cleavage from the solid support was achieved
with
mixture of ammonia methylamine (1:1, AMA) for 15 min at 65 C, when the
universal linker
was used, the deprotection was left for 90 min at 6.5 C or solid supports were
heated with
aqueous ammonia (28%) solution at 55 C for 8 h to deprotect the base labile
protecting
groups. After filtering to remove the solid support, the deprotection solution
was removed
under vacuum in a GeneVac centrifugal evaporator. Tables 1-3 depicts exemplary
structures
of 2'-0Me, 2'4140E, and LNA phosphoramidite monomers
Table 1: 2'-0114e Phosphoramidite Monomers
0
,
DMTO----1\_0 N-
M/1 ,4/
2'4e-A Phosphoramidite
bcH3
,Pµ
No0
crj NH
DMT0.---\\A{
2'-0Me-C Phosphoramidite
'OCH,
-19-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
0
TI(NH 0
DMT0A0.70N-
N
2"-OMe-G Phosphoramidite H
bcH3
us,
NC-Y-.()AN--V
0
/1 NH
DMTO a
2"-OMe-t1 Phosphoramidite -AO/
ci bCHNC
Table 2: 2'-MOE Phosphoramidite Monomers
N . hiTh
\õ--J
DMT0---\coyN--\\N,,,
2'-M0E-A Phosphoramidite
NC
0
NH
\ N
A -4,
-M0E-(5 tn)C. Phosphoramidite DMTO aN 0
s7P:
NCO
0
H3C 0
-20-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
0
NJç
NH
i 0
2.
DMT0A0,7,N- dy,
" N
-1140E-G Phosphoramidite
H3C0
NH
DMT0osioN0
2"-M0E-T Phosphoramidite
4
H3C0
Nc,,/"."011
Table 3: 2'4_,NA Phosphoramidite Monomers
HN
\
\ N
MATO
1_,NA-A Phosphoramidite
(5 0
P\
-21-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
0
1/7NH
-
LNA-(5m)C Phosphorami dite
NCOJ
P\
0
111 NH n
DILITO
LNA-G Phosphoramidite /
b
P\
0
/1 NH
DMTO
LNA-T Phosphoramidite
co
P\
NC--/-0/
[0072] The AmNA. and Scp-BNA. phosphoramidite monomers of 6-N-
benzoyiadenosine (ABn,
) 4-N-acetylcytidine (Cm), 2-N-isobutyrylguanosine (GiBu), and
Thymidine (T) received from LITXNA Technologies. All the monomers were dried
in a
vacuum desiccator with desiccants (P205, at room temperature for 24 hours).
For the AmNA-
PS-DNA-PS and scp-BNA-PS-DNA-PS modifications, the synthesis was carried out
on a I
itM scale in a 3' to 5' direction with the phosphoramidite monomers diluted to
a
concentration of 0.12 M in anhydrous CA-I3CN in the presence of 0.3 M 5-
(benzylthio)-117I-
...11_
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
tetrazole activator (coupling time 16-20 min) to a solid bound oligonucleotide
followed by
modified capping, oxidation and deprotection to afford the modified
oligonucleotides. The
stepwise coupling efficiency of all modified phosphoramidites was more than
97%. The
DUFF (dimethylamino-methylidene) amino)-3H-1, 2, 4-dithiazaoline-3-thione was
used as
the sulfur-transfer agent for the synthesis of the oligoribonucleotide
phosphorothioates.
Oligonucleotide-bearing solid supports were washed with 20% DEA solution in
acetonitrile
for 15 min then the column was washed thoroughly with AcCN. The support was
heated at
65 C with Diisopropylamine:water:Methanol (1:1:2) for 5 h in heat block to
cleave from the
support and deprotect the base labile protecting groups. Tables 4 and 5
depicts exemplary
structures of the AmNA and Scp-BNA phosphoramidite monomers.
Table 4: am-NCH3 Phosphoramidite Monomers
---
0MTC-% 0
Nit N
am-NCH3-A phosphoramidite
u
d
P\
NCO N--
0
, NH
DIV1TO 0 N-
.40
am-NC1T13-(51n)C phosphoramidite
0
N
c-
-23-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
e41( NH 0
DM TO X-4\
N
arn-NCH3-G Phosphorarnidite 0 H
N
-s-
P,
N
0
I(NH
DMTO 0 NA0
am-NC7113-T Phosphoramidite
0'
P,
NC-Y.-CC INT'
Table 5: Scp-BNA Phosphoramidite Monomers
HNTh
DMTO
"-kr,
N
Scp-BNA-A phosphoramidite
0
NC
P\
N
-24-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
H
\ N
DM 10 0 N
Scp-BNA-(5m)C phosphoramidite
- 0
=
-NH 0
D M TO --- ,041
N
Scp-BNA-G Phosphoramidite
6
NC-Y-13' IN' _____________________________________ 7-
\e(Nhi
DM TO ---- oNotN---µ0
Scp-BNA-T Phosphoramidite
q 0
N
\
[0073] The cholesterol, tocopherol phosphoramidite, and solid supports
were
received from CheinGenes. The cholesterol and Tocopherol conjugated
oligonucleotides
were obtained by initiating solid phase synthesis on cholesterol and
Tocopherol supports
attached on TEG linker for 3'-conjugation while final coupling of the
phosphoramidite
provided the 5'-conjugated oligonucleotides.
-25-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
5c-Cholesterol with TEG Linker
OH 0õ0 _______________________________________________________ -OH
õ--
3'-Cholesterol with TEG- Linker
HO¨
OH
0
5Ltocophero1-TEG linker
5" 3'
OH 0
\\0
Ii
p-0 OH
0
31-tocopherol-TEG linker
3'
Hi, OH
0 0
0
7:
0
Quantitation of Crude Olig;omer or Raw Analysis
[0074] Samples were dissolved in deionized water (1.0 mi.) and
quantified as
follows: Blanking was first performed with water alone (1.0 trii,), then 20
pi_ of sample and
980 u-L, of water were mixed well in a microfuge tube, transferred to cuvette
and absorbance
reading obtained at 260 mri. The crude material was dried and stored at
-20 C.
Crude IIPLC/LC-MS analysis
[0075! The 0.1 OD of the crude samples were used for crude MS analysis.
After
confirming the crude LC-MS data, the purification step was performed.
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
HPLC Purification
100761 The Phosphodiester (PO), Phosphorothioate (PS) and chimeric
modified
oligonucleotides were purified by anion-exchange HPLC. The buffers were 20 mM
sodium
phosphate in 10% CH3CN, pH 8.5 (buffer A) and 20 mM sodium phosphate in 10%
CH3CN,
1.8 M NaBr, pH 8.5 (buffer B). Fractions containing full-length
oligonucleotides were
pooled, desalted and lyophilized.
[0077] The conjugated oligonucleotides were purified by an in-house
packed
RPC-Source15 reverse-phase column. The buffers were 20 mM sodium acetate in
10%
CH3CN, (buffer A) and CH3CN (buffer B). Fractions containing full-length
oligonucleotides
were pooled, desalted and lyophilized.
Desalting of Purified Oligomer
(00781 The purified dry oligomer was then desalted using Sephadex G-25
M
(Amersham Biosciences). The cartridge was conditioned with 10 rriL of
deionized water
thrice. The purified oligonucleotide dissolved thoroughly in 2.5 mi. deionized
water was
applied to the cartridge with very slow drop wise elution. The salt free
oligomer was eluted
with 3.5 mi.. deionized water directly into a screw cap vial.
Final HPLC and Electrospray LC/MS Analysis
[0079] Approximately 0.10 OD of oligomer is dissolved in water and then
pipetted in special vials for 1EX-HPLC and LC/MS analysis. Analytical HPLC and
ES LC-
MS established the integrity of the chimeric oligonucleotides.
[0080] The cholesterol and tocopherol conjugated sequences were
analyzed by
high-performance liquid chromatography (1-1PLC) on a Luna C8 reverse-phase
column. The
buffers were 20 mM Na0Ac in 10% CH3CN (buffer A) and 20 mM Na0A.c in 70% CH3CN
(buffer B). Analytical HPLC and ES LC-MS established the integrity of the
conjugated
oligonucleotides
Post Synthesis Conjugation:
(00811 5'-Folate conjugated siRNAs: To a solution of 5'-hexylamino
siRNA in
0.1 M sodium tetraborate buffer, pH 8.5 (2 mM) a solution of Folate-NHS ester
(3 mole
-27-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
equivalent) dissolved in MIS() (40 mM) was added, and the reaction mixture was
stirred at
room temperature for 3 h. The Reaction mixture concentrated under reduced
pressure. The
residue was dissolved in water and purified by MIX on a strong anion exchange
column
(GE Healthcare Bioscience, Source 30Q, 30 p.m, 2.54 x 8 cm, A = 100 m11,1
ammonium
acetate in 30% aqueous CH3CN, B = 1.8 M NaBr in A, 0-60% of B in 60 min, flow
10
inLimin). The residue was desalted by in house packed Sephadex G-25 column to
yield the
5'-Folate conjugated siRNAs in an isolated yield of 62-80%. The folate
conjugated siRNAs
were characterized by fEX-HPLC and Thermo Fischer ESI-LC-MS system. Table 6
depicts
exemplary nucleic acids and structures.
oOOH
H 0 LT ___________
9 N N //'
____________________________________________________________________
Oligonucleotides ..
3'
N N
Table 6: Abbreviations for nucleic acid structures
Abbreviation Name Structure
NH2
A Adenine
0
Guanine
NH
NH2
NH,
Cytosine
0
-28-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
Abbreviation Name Structure
0
)NH
Uracil
0
NH
Thymine
0
alp
NH2
(5m)C 5-methyl-cytosine
0
NH2
DAP 2,6-diaminoporine
NH2
Base
.Deoxy
0 0
Ps Phosphorothioate 0,
p 0, /
P
µNO-4 HS/ \O
or
0 Base
in LNA
-29-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Abbreviation Name Structure
i0 Base
am AmNA
0-/=13,1:NH
1
0 Base
scp Scp-BNA
-'-
, 0
Base
0
In 2'-0Me
OCH3
+
Base
0
moe 2'-1\40E
OCH2CH2OCH3
..i0 Base
cet cEt
' Base
gn GNA
[0082] Any of the structures shown in Table 6 can be combined with any
base,
thereby generating various combinations of structures. For example, using the
abbreviations
and structures from Table 6, one skilled in the art -understands that the
abbreviation "AmG"
-30-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
0
0 <INH
N XIL'N N H2
0 represents " NH ."
Furthermore, additional structures not
depicted in the tables, but described elsewhere throughout the application may
be used and
combined with any base described in the tables or elsewhere throughout the
application.
Pharmaceutical Compositions
00831 Some embodiments described herein relate to pharmaceutical
compositions that comprise, consist essentially of, or consist of an effective
amount of an
siRNA described herein and a pharmaceutically acceptable carrier, excipient,
or combination
thereof A pharmaceutical composition described herein is suitable for human
and/or
veterinary applications.
[0084] The terms
"function" and "functional" as used herein refer to a biological,
enzymatic, or therapeutic function.
[0085] The terms
"effective amount" or "effective dose" is used to indicate an
amount of an active compound, or pharmaceutical agent, that elicits the
biological or
medicinal response indicated. For example, an effective amount of compound can
be the
amount needed to alleviate or ameliorate symptoms of disease or prolong the
survival of the
subject being treated This response may occur in. a tissue, system, animal or
human and
includes alleviation of the signs or symptoms of the disease being treated.
Determination of
an effective amount is well within the capability of those skilled in the art,
in view of the
disclosure provided herein. The effective amount of the compounds disclosed
herein required
as a dose will depend on the route of a.dministration, the type of animal,
including human,
being treated, and the physical characteristics of the specific animal under
consideration. The
dose can be tailored to achieve a desired effect, but will depend on such
factors as weight,
diet, concurrent medication and other factors which those skilled in the
medical arts will
recognize.
-3
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0086] The term "pharmaceutically acceptable salts" includes relatively
non-
toxic, inorganic and organic acid, or base addition salts of compositions,
including without
limitation, analgesic agents, therapeutic agents, other materials, and the
like. Examples of
pharmaceutically acceptable salts include those derived from mineral acids,
such as
hydrochloric acid and sulfuric acid, and those derived from organic acids,
such as
ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, and the
like. Examples of
suitable inorganic bases for the formation of salts include the hydroxides,
carbonates, and
bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium,
aluminum, zinc,
and the like. Salts may also be formed with suitable organic bases, including
those that are
non-toxic and strong enough to form such salts. For example, the class of such
organic bases
may include but are not limited to mono-, di-, and trialkylamines, including
methylamine,
dimethylamine, and triethylamine; mono-, di-, or trihydroxyalkylamines
including mono-, di-
and triethanolamine; amino acids, including glycine, arginine and lysine;
guanidine; N-
methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine;
morpholine;
ethylemxliamine; N-benzylphenethylamine; trihydroxymethyl aminoethane.
[0087] "Formulation", "pharmaceutical composition", and "composition"
as used
interchangeably herein are equivalent terms referring to a composition of
matter for
administration to a subject.
[0088] The term "pharmaceutically acceptable" means compatible with the
treatment of a subject, and in particular, a human.
[0089] The terms "agent" refers to an active agent that has biological
activity and
may be used in a therapy. Also, an "agent" can be synonymous with "at least
one agent,"
"compound," or "at least one compound," and can refer to any form of the
agent, such as a
derivative, analog, salt or a prodrug thereof. The agent can be present in
various forms,
components of molecular complexes, and pharmaceutically acceptable salts
(e.g.,
hydrochlorides, hydrobromides, sulfates, phosphates, nitrates, borates,
acetates, maleates,
tartrates, and salicylates). The term "agent" can also refer to any
pharmaceutical molecules or
compounds, therapeutic molecules or compounds, matrix forming molecules or
compounds,
polymers, synthetic molecules and compounds, natural molecules and compounds,
and any
combination thereof.
-32-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0090] The term "subject" as used herein has its ordinary meaning as
understood
in light of the specification and refers to an animal that is the object of
treatment, inhibition,
or amelioration, observation or experiment. "Animal" has its ordinary meaning
as understood
in light of the specification and includes cold- and warm-blooded vertebrates
and/or
invertebrates such as fish, shellfish, or reptiles and, in particular,
mammals. "Mammal" has
its ordinary meaning as understood in light of the specification, and includes
but is not
limited to mice, rats, rabbits, guinea pigs, dogs, cats, sheep, goats, cows,
horses, primates,
such as humans, monkeys, chimpanzees, or apes. In some embodiments, the
subject is
human.
100911 Proper formulation is dependent upon the route of administration
chosen.
Techniques for formulation and administration of the compounds described
herein are known
to those skilled in the art. Multiple techniques of administering a compound
exist in the art
including, but not limited to, enteral, oral, rectal, topical, sublingual,
buccal, intraaural,
epidural, epicutaneous, aerosol, parenteral delivery, including intramuscular,
subcutaneous,
intra-arterial, intravenous, intraportal, intra-articular, intradermal,
peritoneal, intramedullary
injections, intrathecal, direct intraventricular, intraperitoneal, intranasal
or intraocular
injections. Pharmaceutical compositions will generally be tailored to the
specific intended
route of administration. Pharmaceutical compositions can also be administered
to isolated
cells from a patient or individual, such as T cells, Natural Killer cells, B
cells, macrophages,
lymphocytes, stem cells, bone marrow cells, or hematopoietic stem cells.
[0092] The pharmaceutical compound can also be administered in a local
rather
than systemic manner, for example, via injection of the compound directly into
an organ,
tissue, cancer, tumor or infected area, often in a depot or sustained release
formulation.
Furthermore, one may administer the compound in a targeted drug delivery
system, for
example, in a liposome coated with a tissue specific antibody. The liposomes
may be targeted
to and taken up selectively by the organ, tissue, cancer, tumor, or infected
area.
[00931 The pharmaceutical compositions disclosed herein may be
manufactured
in a manner that is itself known, e.g., by means of conventional mixing,
dissolving,
granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping
or tableting
processes. As described herein, compounds used in a pharmaceutical composition
may be
provided as salts with pharmaceutically compatible counterions.
-33-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0094] As used herein, a "carrier" refers to a compound, particle,
solid, semi-
solid, liquid, or diluent that facilitates the passage, delivery and/or
incorporation of a
compound to cells, tissues and/or bodily organs. For example, without
limitation, a lipid
nanoparticle (LAP) is a type of carrier that can encapsulate an
oligonucleotide to thereby
protect the oligonucleotide from degradation during passage through the
bloodstream and/or
to facilitate delivery to a desired organ, such as to the liver.
[0095] As used herein, a "diluent" refers to an ingredient in a
pharmaceutical
composition that lacks pharmacological activity but may be pharmaceutically
necessary or
desirable. For example, a diluent may be used to increase the bulk of a potent
drug whose
mass is too small for manufacture and/or administration. it may also be a
liquid for the
dissolution of a drug to be administered by injection, ingestion or
inhalation. A common
form of diluent in the art is a buffered aqueous solution such as, without
limitation,
phosphate buffered saline that mimics the composition of human blood.
[0096j The term "excipient" has its ordinary meaning as understood in
light of the
specification, and refers to inert substances, compounds, or materials added
to a
pharmaceutical composition to provide, without limitation, bulk, consistency,
stability,
binding ability, lubrication, disintegrating ability etc., to the composition.
Excipients with
desirable properties include but are not limited to preservatives, adjuvants,
stabilizers,
solvents, buffers, diluents, solubilizing agents, detergents, surfactants,
chelating agents,
antioxidants, alcohols, ketones, aldehydes, ethylenediaminetetraacetic acid
(EDTA), citric
acid, salts, sodium chloride, sodium bicarbonate, sodium phosphate, sodium
borate, sodium
citrate, potassium chloride, potassium phosphate, magnesium sulfate sugars,
dextrose,
fructose, mannose, lactose, galactose, sucrose, sorbitol, cellulose, serum,
amino acids,
polysorbate 20, polysorbate 80, sodium deoxycholate, sodium taurodeoxycholate,
magnesium stearate, octylphenol eth.oxylate, benzethonium chloride,
thimerosal, gelatin,
esters, ethers, 2-phenoxyethanol, urea, or vitamins, or any combination
thereof. The amount
of the excipient may be found in a pharmaceutical composition at a percentage
of 0%, 0.1%,
0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%,
8%, 9%,
10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w/w or any percentage
by
weight in a range defined by any two of the aforementioned numbers.
-34-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0097] The term "adjuvant" as used herein refers to a substance,
compound, or
material that stimulates the immune response and increase the efficacy of
protective
immunity and is administered in conjunction with an immunogenic antigen,
epitope, or
composition. Adjuvants serve to improve immune responses by enabling a
continual release
of antigen, up-regulation of cytokines and chemokines, cellular recruitment at
the site of
administration, increased antigen uptake and presentation in antigen
presenting cells, or
activation of antigen presenting cells and inflammasomes. Commonly used
adjuvants include
but are not limited to alum, aluminum salts, aluminum sulfate, aluminum
hydroxide,
aluminum phosphate, calcium phosphate hydroxide, potassium aluminum sulfate,
oils,
mineral oil, paraffin oil, oil-in-water emulsions, detergents, MF590,
squalene, AS03, a-
tocopherol, polysorbate 80, AS04, monophosphoryl lipid A, virosomes, nucleic
acids,
polyinosinic:polycytidylic acid, saponins, QS-21, proteins, flagellin,
cytokines, chemokines,
IL-1, IL-2, IL-12, IL-15, IL-21, imidazoquinolines, CpG oligonucleotides,
lipids,
phospholipids, dioleoyl phosphatidylcholine (DOPC), trehalose dimycolate,
peptidoglycans,
bacterial extracts, lipopolysaccharides, or Freund's Adjuvant, or any
combination thereof
[0098] The term "purity" of any given substance, compound, or material
as used
herein refers to the actual abundance of the substance, compound, or material
relative to the
expected abundance. For example, the substance, compound, or material may be
at least 80,
85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure, including all
decimals in between.
Purity may be affected by unwanted impurities, including but not limited to
side products,
isomers, enantiomers, degradation products, solvent, carrier, vehicle, or
contaminants, or any
combination thereof. Purity can be measured technologies including but not
limited to
chromatography, liquid chromatography, gas chromatography, spectroscopy, UV-
visible
spectrometry, infrared spectrometry, mass spectrometry, nuclear magnetic
resonance,
gravimetry, or titration, or any combination thereof.
Methods of Use
[0099] Some embodiments disclosed herein related to selecting a subject
or
patient in need. In some embodiments, a patient is selected who is in need of
treatment,
inhibition, amelioration, prevention or slowing of diseases or conditions
associated with PD-
L1 dysregulation. In some embodiments, such diseases or conditions associated
with PD-L1
-35-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
dysregulation may include, for example, cancer, HCC, viral infections, or HBV.
In some
embodiments, a patient is selected who has previously been treated for the
disease or disorder
described herein. In some embodiments, a patient is selected who has
previously been treated
for being at risk for the disease or disorder described herein. In some
embodiments, a patient
is selected who has developed a recurrence of the disease or disorder
described herein. In
some embodiments, a patient is selected who has developed resistance to
therapies for the
disease or disorder described herein. In some embodiments, a patient is
selected who may
have any combination of the aforementioned selection criteria.
[0100] siRNA molecules and pharmaceutical compositions comprising siRNA
molecules disclosed herein can be evaluated for efficacy and toxicity using
known methods.
A non-limiting list of potential advantages of an siRNA described herein
include improved
stability, increased safety profile, increased efficacy, increased binding to
the target,
increased specificity for the target (for example, a cancer cell or virally
infected cell).
101011 The terms "treating," "treatment," "therapeutic," or "therapy"
as used
herein has its ordinary meaning as understood in light of the specification,
and do not
necessarily mean total cure or abolition of the disease or condition. The term
"treating" or
"treatment" as used herein (and as well understood in the art) also means an
approach for
obtaining beneficial or desired results in a subject's condition, including
clinical results.
Beneficial or desired clinical results can include, but are not limited to,
alleviation or
amelioration of one or more symptoms or conditions, diminishment of the extent
of a disease,
stabilizing (i.e., not worsening) the state of disease, prevention of a
disease's transmission or
spread, delaying or slowing of disease progression, amelioration or palliation
of the disease
state, diminishment of the reoccurrence of disease, and remission, whether
partial or total and
whether detectable or undetectable. "Treating" and "treatment" as used herein
also include
prophylactic treatment. Treatment methods comprise administering to a subject
a
therapeutically effective amount of an active agent. The administering step
may consist of a
single administration or may comprise a series of administrations. The
compositions are
administered to the subject in an amount and for a duration sufficient to
treat the patient. The
length of the treatment period depends on a variety of factors, such as the
severity of the
condition, the age and genetic profile of the patient, the concentration of
active agent, the
activity of the compositions used in the treatment, or a combination thereof.
It will also be
-36-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
appreciated that the effective dosage of an agent used for the treatment or
prophylaxis may
increase or decrease over the course of a particular treatment or prophylaxis
regime. Changes
in dosage may result and become apparent by standard diagnostic assays known
in the art. In
some instances, chronic administration may be required.
[0102] Some embodiments described herein relate to a method of
treating,
inhibiting, ameliorating, preventing, or slowing the disease or disorder
described herein. In
some embodiments, the methods include administering to a subject identified as
suffering
from the disease or disorder described herein an effective amount of an siRNA
described
herein, or a pharmaceutical composition that includes an effective amount of
an siRNA as
described herein. Other embodiments described herein relate to using an siRNA
as described
herein in the manufacture of a medicament for treating, inhibiting
ameliorating, preventing,
or slowing the disease or disorder described herein. Still other embodiments
described herein
relate to the use of an siRNA as described herein or a pharmaceutical
composition that
includes an effective amount of an siRNA as described herein for treating,
inhibiting
ameliorating, preventing, or slowing the disease or disorder described herein.
[0103] Some embodiments described herein relate to a method for
inhibiting
replication of a cancer cell or a virus that can include contacting the cell
or virus or
administering to a subject identified as suffering from a cancer or a viral
infection with an
effective amount of an siRNA described herein, or a pharmaceutical composition
that
includes an effective amount of an siRNA described herein. Other embodiments
described
herein relate to the use of an effective amount of an siRNA described herein,
or a
pharmaceutical composition that includes an effective amount of an siRNA
described herein
in the manufacture of a medicament for inhibiting replication of a cancer cell
or virus. Still
other embodiments described herein relate to an effective amount of an siRNA
described
herein, or a pharmaceutical composition that includes an effective amount of
an siRNA
described herein for inhibiting replication of a cancer cell or virus. In some
embodiments, the
cancer cell is an HCC cell. In some embodiments, the virus is hepatitis B.
[0104] Some embodiments described herein relate to a method for
inhibiting cell
proliferation, such as inhibiting cell proliferation of a cancer cell or cell
infected with a virus,
that can include administering to a subject identified as suffering from a
disease wherein
inhibiting cell proliferation is desirable with an effective amount of an
siRNA described
-37-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
herein, or a pharmaceutical composition that includes effective amount of an
siRNA
described herein. Other embodiments described herein relate to the use of an
effective
amount of an oligonucleotide described herein, or a pharmaceutical composition
that includes
an effective amount of an siRNA described herein in the manufacture of a
medicament for
inhibiting cell proliferation, such as inhibiting cell proliferation of a
cancer cell or cell
infected with a virus. Still other embodiments described herein relate to an
effective amount
of an siRNA described herein, or a pharmaceutical composition that includes an
effective
amount of an siRNA described herein for inhibiting cell proliferation, such as
inhibiting cell
proliferation of a cancer cell or cell infected with a virus. In some
embodiments, the cancer
cell is an HCC cell. In some embodiments, the cell infected with a virus is
infected with
hepatitis B virus.
101051 Some embodiments described herein relate to a method of inducing
apoptosis of a cell (for example, a cancer cell or cell infected with a virus)
that can include
contacting the cell with an effective amount of an siRNA described herein, or
a
pharmaceutical composition that includes an effective amount of an siRNA as
described
herein. Other embodiments described herein relate to using an effective amount
of an siRNA
as described herein or a pharmaceutical composition that includes an effective
amount of an
siRNA in the manufacture of a medicament for inducing apoptosis of a cell,
such as a cancer
cell or cell infected with a virus. Still other embodiments described herein
relate to the use of
an effective amount of an siRNA as described herein or a pharmaceutical
composition that
includes an effective amount of an siRNA as described herein for inducing
apoptosis of a
cell, such as a cancer cell or cell infected with a virus. In some
embodiments, the cancer cell
is an HCC cell. In some embodiments, the cell infected with a virus is
infected with hepatitis
B virus.
[0106] Some embodiments described herein relate to a method of
decreasing the
viability of a cell (for example, a cancer cell or cell infected with a virus)
that can include
contacting the cell with an effective amount of an siRNA described herein, or
a
pharmaceutical composition that includes an effective amount of an siRNA as
described
herein. Other embodiments described herein relate to using an siRNA as
described herein in
the manufacture of a medicament for decreasing the viability of a cell, such
as a cancer cell
or cell infected with a virus. Still other embodiments described herein relate
to the use of an
-38-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
effective amount of an siRNA as described herein or a pharmaceutical
composition that
includes an effective amount of an siRNA as described herein for decreasing
the viability of
a cell, such as a cancer cell or cell infected with a virus. In some
embodiments, the cancer
cell is an FICC cell. in some embodiments, the cell infected with a virus is
infected with
hepatitis B virus.
10107! In some embodiments, the effective amount of an siRNA for a
human
subject is 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 pg, or
1, 10, 20, 30,
40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200,
300, 400, 500,
600, 700, 800, 900, 1000 mg or any amount within the range defined by any two
aforementioned amounts. In some embodiments, the effective amount of an siRNA
for a
human subject is 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000
na/kg, or 1, 10,
20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180,
190, 200, 300,
400, 500, 600, 700, 800, 900, 1000 gg/kg or any amount within the range
defined by any two
aforementioned amounts. In some embodiments, the effective amount of an siRNA
is dosed
more than one time. In some embodiments, the siRNA dose is administered every
1, 2, 3, 4,
5, 6, 7 days, or 1, 2, 3, 4 weeks, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
months, or 1, 2, 3, 4, 5
years, or any period or combination thereof within the range defined by any
two
aforementioned times. In some embodiments, at least one loading dose and at
least one
maintenance dose is administered to the subject, where the at least one
loading dose is a
higher dose of the siRNA than the at least one maintenance dose.
[01081 As used herein, the term "combination therapy" is intended to
define
therapies which comprise the use of a combination of two or more
pharmaceutical
compounds/agents or therapies. Thus, references to "combination therapy",
"combinations"
and the use of compounds/agents "in combination" in this application may refer
to
compounds/agents that are administered as part of the same overall treatment
regimen. As
such, the dosage or timing of each of the two or more compounds/agents may
differ: each
may be administered at the same time or at different times. Accordingly, the
compounds/agents of the combination may be administered sequentially (e.g.
before or after)
or simultaneously, either in the same pharmaceutical formulation (i.e.
together), or in
different pharmaceutical formulations (i.e. separately). Each of the two or
more
-39-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
compounds/agents in a combination therapy may also differ with respect to the
route of
administration.
[0109] The term "inhibitor", as used herein, refers to an enzyme
inhibitor or
receptor inhibitor which is a molecule that binds to an enzyme or receptor,
and decreases
and/or blocks its activity. The term may relate to a reversible or an
irreversible inhibitor.
101101 Cancer may be treated with surgery, radiation therapy,
chemotherapy,
targeted therapies, immunotherapy or hormonal therapies. Any of these
mentioned therapies
may be used in conjunction with another therapy as a combination therapy.
Chemotherapeutic compounds include but are not limited to alemtuzumab,
altretamine,
azacitidine, bendamustine, bleomycin, bortezomib, busulfan, cabazitaxel,
capecitabine,
carboplatin, carmofur, carmustine, chlorambucil, chlormethine, cisplatin,
cladribine,
clofarabine, cyclophosphamide, cytarabine, dacarbazine, dactinomycin,
daunorubicin,
decitabine, denosumab, docetaxel, doxorubicin, epirubicin, estramustine,
etoposide,
everolimus, floxuridine, fludarabine, fluorouracil, fotemustine, gemcitabine,
gemtuzuinab,
hydroxycarbamide, ibritumomab, idarubicin, ifosfamide, irinotecan,
ixabepilone, lomustine,
melphalan, mercaptopurine, methotrexate, mitomycin, mitoxantrone, nedaplatin,
nelarabine,
ofatumumab, oxaliplatin, pad itaxel, pemetrexed, pentostatin, pertuzumab,
procarbazine,
raltitrexed, streptozotocin, tegafur, temozolomide, temsirolimus, teniposide,
tioguanine,
topotecan, tositumomab, valrubicin, vinblastine, vincristine, vindesine,
vinflunine, or
vinorelbine, or any combination thereof.
[0111] As used herein, the term "protein kinase inhibitor" refers to
inhibitors of
protein kinases, serine/threonine kinases, tyrosine kinases, or dual-
specificity kinases for the
treatment of cancer or other illness. In some embodiments, the protein kinase
inhibitor is a
small molecule, compound, polysaccharide, lipid, peptide, polypeptide,
protein, antibody,
nucleoside, nucleoside analog, nucleotide, nucleotide analog, nucleic acid, or
oligonucleotide. In some embodiments, the protein kinase inhibitor includes
but is not limited
to acalabrutinib, adavosertib, afatinib, alectinib, axitinib, binimetinib,
bosutinib, brigatinib,
cediranib, ceritinib, cetuximab, cobimetinib, crizotinib, cabozantinib,
dacomitinib, dasatinib,
entrectinib, erdafitinib, erlotinib, fostamatinib, gefitinib, ibrutinib,
imatinib, lapatinib,
lenvatinib, lestaurtinib, lortatinib, masitinib, momelotinib, mubritinib,
neratinib, nilotinib,
nintedanib, olmutinib, osimertinib, pacritinib, panitumumab, pazopanib,
pegaptanib,
-40-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
ponatinib, radotinib, regorafenib, rociletinib, ruxolitinib, selumetinib,
semaxanib, sorafenib,
sunitinib, SU6656, tivozanib, toceranib, trametinib, trastuzumab, vandetanib,
or vemurafenib,
or any combination thereof.
101121 As used herein, the term "checkpoint inhibitor" refers to an
immunotherapy that targets immune checkpoints to stimulate immune function. In
some
embodiments, the checkpoint inhibitor is a small molecule, compound,
polysaccharide, lipid,
peptide, polypeptide, protein, antibody, nucleoside, nucleoside analog,
nucleotide, nucleotide
analog, nucleic acid, or oligonucleotide. In some embodiments, the immune
checkpoint is the
PD-1/PD-L1 checkpoint. In some embodiments, the PD-1 checkpoint includes but
is not
limited to nivolumab, pembrolizumab, spartalizumab, cemiplimab, camrelizumab,
sintilimab,
tislelizumab, toripalimab, AMP-224 or AMP-514, or any combination thereof. In
some
embodiments, the PD-Ll checkpoint inhibitor includes but is not limited to
atezolizumab,
avelumab, durvalumab, KN035, AUNP12, CA-170, or BMS-986189, or any combination
thereof. In some embodiments, the immune checkpoint is the CTLA-4 checkpoint.
In some
embodiments, the CTLA.-4 checkpoint inhibitor includes but is not limited to
ipilimumab or
tremilimumab, or any combination thereof
[0113] As used herein, the term "VEGF inhibitor" refers to inhibitors
of vascular
endothelial growth factor (VEGF) or a VEGF receptor (VEGFR). In some
embodiments, the
VEGF inhibitor is a small molecule, compound, polysaccharide, lipid, peptide,
polypeptide,
protein, antibody, nucleoside, nucleoside analog, nucleotide, nucleotide
analog, nucleic acid,
or oligonucleotide. In some embodiments, the VEGF inhibitor includes but is
not limited to
aflibercept, axitinib, bevacizumab, brivanib, cabozantinib, cediranib,
lenvatinib, linifinib,
nintedanib, pazopanib, ponatinib, ramucirumab, regorafenib, semaxanib,
sorafenib, sunitinib,
tivozanib, toceranib, or vandetanib, or any combination thereof
[0114] As used herein, the term "antiviral medication" refers to a
pharmaceutical
composition administered to treat a viral infection. In some embodiments, the
viral infection
is caused by adenovirus, Ebola virus, coronavirus, Epstein-Barr virus (EBV),
Friend virus,
hantavirus, hepatitis B virus (HBV), hepatitis C virus (HCV), herpes simplex
virus, human
immunodeficiency virus (HIV), human metapneumovirus, human papillomavirus
(HPV),
influenza virus, Japanese encephalitis virus, Kaposi's sarcoma-associated
herpesvirus,
lymphocytic choriomeningitis virus, parainfluenza virus, rabies virus,
respiratory syncytial
-41-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
virus, rhinovirus, varicella zoster virus. In some embodiments, the antiviral
medication is a
small molecule, compound, polysaccharide, lipid, peptide, polypeptide,
protein, antibody,
nucleoside, nucleoside analog, nucleotide, nucleotide analog, nucleic acid, or
oligonucleotide. In some embodiments, the antiviral medication is an
interferon, a capsid
assembly modulator, a sequence specific oligonucleotide, an entry inhibitor,
or a small
molecule immunomodulatory. In some embodiments, the antiviral medication
includes but is
not limited to AB-423, AB-506, ABI-H2158, ABI-H0731, acyclovir, adapromine,
adefovir,
alafenamide, amantadine, asunaprevir, baloxavir marboxil, beclabuvir,
boceprevir, brivudine,
cidofovir, ciluprevir, clevudine, cytarabine, daclatasvir, danoprevir,
dasabuvir, deleobuvir,
dipivoxil, edoxudine, elbasvir, entecavir, faldaprevir, famciclovir,
favipiravir, filibuvir,
fomivirsen, foscamet, galidesivir, ganciclovir, glecaprevir, GLS4,
grazoprevir, idoxuridine,
imiquimod, IFN-a, interferon alfa 2b, JNJ-440, JNJ-6379, lamivudine,
laninamivir,
ledipasvir, mericitabine, methisazone, MK-608, moroxydine, narlaprevir,
NITD008, NZ-4,
odalasvir, ombitasvir, oseltamivir, paritaprevir, peginterferon alfa-2a,
penciclovir, peramivir,
pibrentasvir, pimodivir, pleconaril, podophyllotoxin, presatovir, radalbuvir,
ravidasvir,
remdesivir, REP 2139, REP 2165, resiquimod, RG7907, ribavirin, rifampicin,
rimantadine,
ruzasvir, samatasvir, setrobuvir, simeprevir, sofosbuvir, sorivudine,
sovaprevir, taribavirin,
telaprevir, telbivudine, tenofovir, tenofovir disoproxil, triazavirin,
trifluridine, tromantadine,
umifenovir, uprifosbuvir, valaciclovir, valgancicovir, vaniprevir,
verlroprevir, velpatasvir,
vidarabine, voxilaprevir, or zanamivir, or any combination thereof.
[0115] The term "% w/w" or "% wt/wt" as used herein has its ordinary
meaning
as understood in light of the specification and refers to a percentage
expressed in terms of the
weight of the ingredient or agent over the total weight of the composition
multiplied by 100.
The term "% v/v" or "% vol/vol" as used herein has its ordinary meaning as
understood in
the light of the specification and refers to a percentage expressed in terms
of the liquid
volume of the compound, substance, ingredient, or agent over the total liquid
volume of the
composition multiplied by 100.
[0116] The invention is generally disclosed herein using affirmative
language to
describe the numerous embodiments. The invention also includes embodiments in
which
subject matter is excluded, in full or in part, such as substances or
materials, method steps
and conditions, protocols, or procedures.
-42-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
EXAMPLES
[0117] Some aspects of the embodiments discussed above are disclosed in
further
detail in the following examples, which are not in any way intended to limit
the scope of the
present disclosure. Those in the art will appreciate that many other
embodiments also fall
within the scope of the invention, as it is described herein above and in the
claims.
Example 1: siRNA design
[01181 siRNAs of 18-21 nucleotides in length were selected. Mismatches
were
allowed only outside of the seed region on the antisense strand, as shown in
Table 7. The
seed region is in positions 2-8, with the position numbering based on the
antisense strand.
The strand length excludes the two nucleotide overhang.
Table 7: Allowed mismatch positions in siRNAs
siRNA Maximum Fully conserved
Allowed mismatch positions
length mismatches positions (seed region)
18 1,9, 10, 11, 12, 13, 14, 15, 16, 17,
18
19 2 2-8 1,9, 10, 11, 12, 13, 14, 15, 16,17, 18,
19
2 2-8 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,
19,
20
20
1, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,
21 2-8
20,21
Example 2: siRNAs targeting the human CD274 gene (PD-L1)
[0119] siRNAs were designed using the human CD274 mRNA transcript (NCBI
accession number NM 014143.4, 3634 at in length. SEQ m NO: I) as the template.
18-mers
are listed in Table 8 (SEQ m NOs: 2-93). 19-mers are depicted in Table 9 (SEQ
ID NOs: 94-
167 and 283-380). 20-mers are depicted in Table 10 (SEQ ID NOs: 168-229). 21 -
mers are
depicted in Table I (SEQ ID NOs: 230-282). All of the listed siRNAs depict the
antisense
strand. Sense strands (which are not listed) are perfectly complementary to
each listed
antisense strand.
[0120] Any of the siRNAs listed herein, and the individual nucleobases,
sugars,
linkages, nucleosides, nucleotides and additional moieties thereof, can be
constructed and
-43-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
used with any of the modifications described herein. The sequences listed in
Tables 8-11 and
SEQ. ID NOs: 2-380 represent the unmodified oligonucleotide sequence prior to
application
of modifications.
Table 8: CD274 siRNAs .-- 18-mers
Target start Target positions siRNA. Antisense Strand
SEQ. ID NO:
position spanned , Sequence
69 86-69 A.0 AGC A A A.TATCCTCATC 7
70 87-70 GACAGCAAATATCCTCAT 3
71 88-71 AGA CAGCAAA TA.TCCTCA. 4
72 89-72 AAGACAGCAAATATCCTC 5
73 90-73 AAAGACAGCAAA.TATCCT 6
74 91-74 TAAAGACAGCAAATATCC 7
75 92-75 A TAAAGACAGCAAATATC 8
76 93-76 TATAAAGACAGCAAATAT , 9
94-77
77 ATATA A AGA CAGCAAA TA. 10
78 95-78 AA.TA.TAAA.GACA.GCAAAT 11
1398 1415-1398 AGACTCAAAATAAATAGG 12
1399 1416-1399 CAGA.CTCAAAATAAATAG 13
1400 1417-1400 , AC AGACFC AAAATAAATA 14
1401 1418-1401 CA.CAGACTCAAAATAAAT 15
1402 1419-1402 TcACAGACTCAAAATAAA 16
1403 1420-1403 CTCACAGACTCAAAA.TAA 17
1404 1421-1404 CCTCACAGACTCAAAATA 18
1405 1422-1405 ACCTC ACA.GACTCAAAAT 19
1406 1423-1406
GACCTCACAGACTCAAAA , 20
1407 1424-1407 AGACCTC ACA GA CTCAAA 21
2700 2717-2700 ATAACTTAGAAACAAAGA 77
_
2701 2718-2701 GA.TA ACTTAGAA A CAA AG 23
2702 2719-2702 AGATAACTTAGAAACAAA , 24
277 294-277 CTTCA.GGTCTT.CCTCTCC 25
-44-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siR NA Antisense Strand
, SEQ ID NO:
position spanned Sequence
3038 3055-3038 GGTAGCTAGCAGTCA.AGG 26
3039 3056-3039 GGG'FAGCTAGCAGTCAAG 27
3040 3057-3040 AGGGTAGCTA.GCAGTCAA 28
3041 3058-3041 , CAGGGTAGCTAGCAG'FCA 29
3239 3256-3239 TICAGCCTTGA.CATGTGG 30
3240 3257-3240 CTFCAGCCITGACAIGTG 31
3241 3258-3241 TCITCAGCCTTGACAIGT 32
3242 3259-3242 TTCTTCAGCCTTGACATG 33
, --
3243 3260-3243 TTTCTTCAGCCTTGACAT 34
350 367-350 GAAGTGCAGCATTTCCCA 35
351 368-351 TGAAGTGCACiCATITCCC 36
352 369-352 CTGAAGTGCAGCATTTCC 37
3527 3544-3527 TTTATTAAATTAATGCAG 38
3528 3545-3528
TTTTATTAAATTAATGCA , 39
3529 3546-3529 A.TTTTATTA A A TTA A TCX7 40
353 370-353 TCTGAAGTGCA.GCA.TTTC 41
354 371-354 ATCTGAAGTGCAGCATTF 42
3542 3559-3542 AATAAATAAGAA.TA.TTTT 43
355 372-355 , GATCTGAAGTGCAGCATF 44
363 380-363 ACATCTGTGATCTGAAGT 45
364 381-364 CACATCTGTGA'FCTGAAG 46
365 382-365 TCACATCTGTGA.TCTGAA 47
366 383-366 TTCACATCTGTGATCTGA 48
414 431-414 GCACC.ACCATAGCTGATC 49
415 432-415
GGCACCACCATAGCTGAT , 50
423 440-423 ITGIAGTC(X3CACCACCA 51
424 441-424 CTIGTAGTCGGCACCACC 52
432 449-432 GTAATTCGCTIGTAGTCG 53
433 450-433 AGTAATTCGCTTGTAGTC 54
-45-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siR NA Antisense Strand
SF Q ID NO:
position spanned Sequence i
451 468-451 TGGGGCATTGACTITCA.0
55
452 469-452 ATGGGGCA'FTGAC1TTCA
56
453 470-453 TAIGGGGCA.TTGACTTTC
57
454 471-454 , G'FATGGGGCATTGACITT 58
455 472-455 TGTATGGGGCATTGACTT
59
456 473-456 TTGTA'FGGGGCATTGAC'F
60
457 474-457 GTTGTA.TGGGGCATTGA.0
61
458 475-458 TGTTGTATGGGGCATTGA
62
...,
459 476-459 TTGTTGTATGGGGCATTG
63
460 477-460 TTTGTTGTATGGGGCATT
64
461 478-461 TITTGTIGTATGGGGCAT
65
462 479-462 ATTTTGTTGTATGGGGCA
66
...,
463 480-463 GATITTGTTGTATaX3GC
67
464 481-464 , TGATTTTGTTGTATGGGG
68
473 490-473 TTCITTGGTTGATTFTGT
69
474 491-474 A.TTCTITGGTTGATTTTG
70
475 492-475 AA'FTCT1TGGTTGATTIT
71
476 493-476 AAA.TTCTITGGTTGATTT
72
477 494-477 , AAAATTCTTIGG'FTGATF 73
499 516-499 A.GAGGTGA.CTGGATCCA.0
74
500 517-500 CAGAGGTGACTGGATCCA
75
501 518-501 TCAGAGGTGACTGGATCC
76
520 537-520 CTGACATGTCAGTTCATG
77
531 548-531 TAGCCCTCAGCCTGACAT
78
564 581-564 TCACTGCTTGTCCAGATG
79
565 582-565 GTCACTGCTTGTCCAGAT
80
566 583-566 GGICACTGCTIGTCCAGA
81
567 584-567 TGGICACTGCTTGTCCAG
82
641 658-641 GTGTGCTGGTCACATTGA
83
-46-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antiserise Strand
SF Q ID NO:
position spanned Sequence ,
642 659-642 AGIGTGCTGGTCA.CATIG 84
643 660-643 CAGTG'FGCIGGICACATT 85
644 661-644 TCAGTGTGCTGGICACA.T 86
645 662-645 , CTCAG'FGTGCIGGTCACA 87
742 759-742 AGGTAGTICTGGGATGAC 88
743 760-743 GAGGTAG1TCTGGGA'FGA 89
893 910-893 TCT.TTGA.GTTTGTA.TCTT 90
894 911-894 TTCTTTGAGITTGTATCT 91
...,
918 935-918 TCCTCCAAATGTGTATCA. 92
919 936-919 CTCCTCCAAATGTGTATC 93
_ ______________________________________________________________________
Table 9: CD274 siRNAs ¨ 19mers
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
position spanned , Sequence .
69 87-69 GACAGCAAATA.TCCTCATC
94
70 88-70 AGACA GCAAATATCCTC
AT 95
71 89-71 ,
AAGACAGCAAATATCCFCA 96
72 90-72 AAAGACA GC
AAATATCCTC 97
73 91-73 ,
TAAAGACAGCAAATA'FCCT 98
74 92-74 ATAAAGACAGCAAATA.TCC
99
75 93-75 ,
TATAAAGACAGCAAATATC 100
76 94-76 ATATAAAGACAGCAAATAT
101
77 95-77 AATATAAAGACAGCAAATA
102
78 96-78 GAATATAAAGACAGCAAAT
103
1398 1416-1398 CAGACTCAAAATAAATAGG
104
1399 1417-1399 ,
ACAGACTCAAAATAAATAG 105
1400 1418-1400 CACAGACTCAAAATAAATA
106
1401 1419-1401 TCACAGACTCAAAATAAAT
107
1402 1420-1402 CTCACAGACTCAAAATAAA
108
1403 I 1421-1403 CCTCACAGACTCAAAATAA 109
----------- 1-- ,
1404 ' 1422-1404
1 ACCTCACAGACTCAAAATA
110
-47-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
position spanned Sequence ,
1405 1423-1405
CiACCTCA.CAGACTCAAAAT 111
1406 1424-1406 AGACCICACAGACFCAAAA
112
2700 2718-2700
GATAACITA.GAAACAAAGA 113
2701 2719-2701 AGATAACTTAGAAACAAAG
114
3038 3056-3038 GGGTAGCTAGCAGTCAAGG
115
3039 3057-3039 ,
AGGGTAGCTAGCAGTCAAG , 116
3040 3058-3040
CACX;GTA.GCTAGCAGTCAA 117
3239 3257-3239 CITCAGCCTTGACATGIGG
1 1 8
------------ 1--
3240 3258-3240
TCITCAGCC'FTGACAIGTG 119
3241 3259-3241
T.TCTTCAGCCTTGACATGT 120
3242 3260-3242 ,
TITCTICAGCCITGACATG 121
3243 3261-3243
GTTTCTTCA.GCCTIGACAT 122
350 368-350
TGAAGTGCACiCATTICCCA 123
,
351 369-351
CTGAAGIGCAGCA.TTTCCC 124
352 370-352 TCTGAAGTGCAGCATTTCC
125
3527 3545-3527
TETTATTAAATTAATGCA.G 126
3 528 3546-3528 ATTTTATTAAATTAATGCA
127
353 371-353 ,
ATCTGAAGTGCAGCATTTC 128
354 372-354
GATCTGAA.GTGCA.GCATTT 129
355 373-355 TGATCTGAAGTGCAGCAIT
130
364 382-364
ICACA.TCTGTGATCTGAA.G 131
365 383-365 ITCACATCIGTGATCTGAA
132
..
415 433-415
CGGCACCACCATACiCTGAT 133
423 441-423 CTTGTAGTCGGCACCACCA
, 134
424 442-424
GCTTGTAGTCCX;CACCACC 135
451 469-451 ATGGGGCATTGACITTCAC
136
------------ 1--
452 470-452
TATGGGGCATTGACT.TTCA 137
453 471-453
GTA.TGGGGCATTGACTTIC 138
454 472-454 IGTATGGGGCATTGACTIT
139
1
455 473-455
T.TGTA.TGGGGCATT'GA.CTT 140
456 474-456 GTTGIAIGGGGCAITGACT
141
457 475-457 TGTTGIATGGGGCATTGAC
142
-48-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
, position spanned Sequence ,
458 476-458 TTGTTGTATGGGGCATTGA 143
459 477-459 TTIGITGIATGGGGCA'FTG 144
460 478-460 T.TTIGTTGTAIGGGGCA TT 145
461 479-461 ATTITG'FTGTATGGGGCAT 146
...
462 480-462 GA TTITGTTGTA.TGGGCX; A 147
463 481-463 , TGATTTTGTTGTATGGGGC , 148
464 482-464 TTGATTFTGTIGIATGGCX3 149
473 491-473 ATTCTTTGGTTGATTTTGT 150
------------ I.
474 492-474 AATFCTTIGGITGATTITG 151
475 493-475 AAATTCT.TTGGTTGATTTT 152
476 494-476 , AAAATFCTTTGGITGAITT 153 ,
499 517-499 CAGAGGTGACTGGATCC AC 154
500 518-500 TCAGAGGTGACTGGATCCA 155 ....
520 538-520 CCTGACATGTCAGTTCA TG 156
564 582-564 GTCACTGCTTGTCCAGATG 157
565 583-565 GGTCACTCiCTTGTCCAGA.T 158
566 584-566 TGGTCACTGCTTGTCCAGA , 159
567 585-567 , A TGGTC ACTGCTTGTCCAG 160
641 659-641 A.GTGTGCTGGICACATTGA. 161
642 660-642 CAGIG1 GC 1 GGTCACATTG 162
643 661-643 TC A GTGIGCTGGTCA.0 ATT 163
644 662-644 crcAGIGTGCTGGTCACA'F 164
893 911-893 TICTITGA.GTTTGTA.TCTT 165
918 936-918 , CTCCTCCAAATGTGTATCA , 166
919 937-919 TCTCCTCCAAATGTGTATC 167
--- 23 ----------- 41-23 AACiCGCGGCTGGTCiCGGAG 283
t
43 61-43 AATGCCCTGCAGGCGGACA 284
103 121-103 CGTFCAGCAAATGCCAGTA 285
123 141-123 GGGAA.CCGTGA.CAGTAAAT 286
1
143 161-143 IC'FACCACA'FATAGG'FCCT 287
163 1. 81.-163 TTGICATATIGCTACCA.TA. 288
183 201-183 TACTGGGAATTTGCATTCA 289
-49-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ 11) NO:
, position spanned Sequence i
203 221-203 GCCAGGTCTAATTGTITTF
290
223 241-223
CCCAATAGA.CAA.TTAGTGC 291
263 281-263 TcrccAmcACAAATTGAA
292
283 301-283
GCTGAA.CCTTCA.GGTCTIC 293
303 321-303 CCTCTGTCTGTAGCTACTA
294
323 341-323
TGGTCCTTCAACAGCCGGG , 295
543 561-543 TTCGGCCTFGGGGTAGCCC
296
603 -------- I. 621-603 GGAATTGGTGGTGGTGGTC
297 ...,
723 741-723
CAA.T.TCA.GCTGTATGGTTT 298
763 781-763 TITCATFTGGAGGATGTGC
299
803 821-803 ,
AGGCA.TAATAA.GATGGCTC 300 ,
823 841-823 TGAATGICAGIGCTACACC
301
843 861-843 CCCT.TTTCTTAAACGGAAG
302
863 881-863 'FTTTTCACATCCATCATTC
303
963 981-963 GAGAATCCCTGCTTGAAGA.
304
983 1001-983 GAACCCCTAAACCACAGGT
305
1063 1081-1063 TCAGTGCITGGGCCTTTIA
306
_ .
1083 1101-1083 GCTTTCGCCAGGTTCCATT
307
1183 1201-1183 CCCTG'FCACAGGCGTCGAT
308
1203 1221-1203 TGTICAGAAGTA.TCCTTIC
309
1263 1281-1263 ITAGGGATICTCAACCCGT
310
1283 1301-1283 TGCAGGAACTGACCCTCAA.
311
1323 1341-1323
AAAACAAATTGAGGCATTG 312
1363 1381-1363 ,
ATACTGTCCCGTTCCAACA , 313
1443 1461-1443 AAAAGAAATCATTCACAAC
314
1483 . 1501-1483
TTTGGCGACAAAATTGTAA . 315 ,
1503 1521-1503 TCATTAAGCAGCAAGTTTA
316
1543 1561-1543 CACCITACAAATACICCAT
317
1583 1601-1583 ,
ATGCTTCCAATGTA.TA.CTT 318
i
1603 1621-1603 CAACCAACGGTITGATC1T
319
1623 1641-1623
AA.TAAA.GGTGACATCCTAT 320
1683 1701-1683
ACTGCACAGACACTTGAGG 321
-50-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
, position spanned Sequence ,
1703 1721-1703 GATATTTAAATGGAACAGA
322
1723 1741-1723
TACCA.CATAA.TTGTAAAGC 323
1743 1761-1743 ATGAGATTATGIGTGTAGG
324
1843 1861-1843
ATTTACIGGTTIGGGCAA.G 325
1863 1881-1863 GTGGCAGTCTGAGGTCTGC
326
1883 1901-1883 GTATTATAAAAGGACAGTG
, 327
1903 1921-1903
GTAAAATATAGCTGTAAA'r 328
1923 -------------------- 1941-1923 GAATAAAAGAATTGCTTAA
329
4-
1943 1961-1943
GCA.CTTAATAAA.TGGTITT 330
1963 1981-1963 CAGCGATTGATATTGCAAG
331
2003 2021-2003 ,
TACTTTGICTTGCTCA.CAT 332 ,
2043 2061-2043
GITAATCTCCTCA'FTATAC 333
2083 2101-2083 TGCTATGACACTGGACTAA
334
,
2123 2141-2123 TTGGCAACACTGCTCGGGT
335
2163 2181-2163 TATCCAACCGTCCCAGACC
336
2203 2221-2203 TGTAAATGAAAATTACTCT
337
2223 2241-2223 ,
TTTAAGTACCGACCTCTCT 338
2263 2281-2263 ,
ATGCTA.GAAAA.GGAATICC 339
2283 2301-2283
GCAAATCAGGAATAAA'FAT 340
2323 2341-2323
CCAGACACTATA.TAAACAA 341
2343 2361-2343
GACAGAACTG'FTAAACAAT 342
2383 2401-2383 AAGGTATGAATTTAAAATT
343
2423 2441-2423 AACCATCTCCCATGGGATC
344
2443 2461-2443 .
GGATGAAGTGGAGATTTTC , 345
2463 2481-2463 GGAAACTTGAATGGCTTGG
346
2483 -------------------- 2501-2483
GTAC3CAGTTGCTTCIGGAA 347
1---
2503 2521-2503 GAACATATGAATGAAAGGC
348
2563 2581-2563 AAAAAAITTFAAAAATACG
349
: 2583 2601-2583 ,
CAATGTGTTACTATTTAGG 350 ,
1
1 2643 2661-2643
CCA'FCTGCTA'FATAAGAAA 351
2663 2681-2663
CTGGGAACTICAAATTCA.T 352
2723 2741-2723 AGATAATGAAAAGCTATGG
353
-51-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
, position spanned Sequence ,
2743 2761-2743 CATATACTGGATCATATGA
354
2763 2781-2763
TA.TATGIAGGACA.TA.TTTA 355
2783 2801-2783 AAATGGTGGTFGTCTAAAT
356
2803 2821-2803 TCCTAGAGCAAATACTTAA
357
2823 2841-2823 ATAAACAAATCCAAACTCT
358
2863 2881-2863 ,
GTGCACCCTGGAGAGCCCA , 359
2883 2901-2883 TTTAGGACTAGATTGACTC
360
--- 2903 -- . 2921-2903 AGTTAATAATAAGATTGCT
361
4-- - . ...,
2923 2941-2923
GACA.TGATTCTGTCATACA 362
2943 2961-2943
AGCAGAAA.ACAAAAGTTCC 363
2983 3001-2983 ,
TGCAAGTACA.GCA.TCAAAG 364 ,
3003 3021-3003
CCAGAAAGAAAATG'FGATF 365
3063 3081-3063 CAACGAATGAGGCTTTTCT
366
,
3083 3101-3083 GGCATTCAAGGGTTCAAGC
367
3103 3121-3103 ----------------------------- GTGTAGTGATGACAGCTGG
368
3183 3201-3183 TGGCCAAGAGGGAAAGGAA
369
3203 3221-3203 TTGTCATMACACCAGAAT
370
3263 3281-3263
GGAGCTCTGTTGGAGACA.0 371
3283 3301-3283 TGTACAAACAGATAACACA
372
3323 3341-3323
ACAA.AGAACA.CTGICACAC 373
3343 3361-3343 AATTCTFGCCIGIAATTCA
374
3383 3401-3383 TAGGAATAGACTGAGTAGA
375
3423 3441-3423 GTGCCTTACAAATCCAACA
376
3443 3461-3443
CATGAGACAAAAGGGA.TAA 377
3463 3481-3463 CTATGCCATTTACGATGAA
378
3563 ------- , 3581-3563 ATGCTGGTGTACCAAGTAA
. 379 ,
1---
3603 3621-3603 TGAACATTTTATTAAACAC
380
Table 10: CD274 siRNAs ¨ 20mers
Target start Target positions siRNA. Antisense Strand
SEQ 1113 NO:=
position spanned , Sequence
70 89-70 AAGACAGCAAATATCCTCAT 168
-52-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
position spanned Sequence
71 90-71 AA AGAC AGC A A ATATCCTCA 169
72 91-72 TA A A GA C AGCA A A TA TCCTC 170
73 92-73 ATA.AAGACAGCAAATATCCT 171
74 93-74 TA TA.AAGACA.GCA .AATATCC 172
75 94-75 ATATAAAGACAGCAAATATC 173
76 95-76 A .ATATAA .AGA.CAGC.AAA.TAT 174
77 96-77 GAA TA TA.AAGACA.GCA .AATA 175
78 97-78 TGAATATA A.AGACAGCAA AT 176
1398 1417-1398 .ACAGACTCAA.AATA.AATAGG 177
1399 1418-1399 CAC AGACTC AAAATAAATAG 178
1400 1419-1400 TCACAGACTCA.AAATAAA.TA. 179
1401. 1420-1401 CIC.ACAGACTCAA.AATA.AAT 180
1402 1421-1402 CCTCACA.GACTCA.AA .AT.AA A 181
1403 1422-1403 .ACCTCACAGACTCA.AAATAA 182
1404 1423-1404 GACCTCACAGACTCA.AAA.TA 183
1405 1424-1405 .AGA.CCIC.ACAGACTCA AAA T 184
2700 2719-2700 A.GA TA ACTIAGA.AACAAA.GA 185
3038 3057-3038 A GGGTA.GCTAGC AGTCA .AGG 186
3039 3058-3039 C AGGGTA GCT.AGC AGTC A A.G 187
3240 3259-3240 TIC TTC A GCCTTGAC A TGTG 188
3241 3260-3241 TITCTICAGCCITGACAIGT 189
3242 3261-3242 GITICITCAGCMGACATG 190
3243 3262-3243 TGTTTCTTc AGCCITGAC AT 191
350 369-350 CIGAAGTGCAGCATTICCCA 192
351 370-351 TCTGAAGTGCAGCATTTccc 193
352 371-352 AICTGAAGIGCAGCATucc 194
353 372-353 GATCTGAAGTGCAGCATITC 195
354 373-354 TGATCTGAAGTGCAGCATTT 196
355 374-355 GTGATCTGAAGTGCAGCAIT 197
364 383-364 TIC ACATCTGTGATCTGAAG 198
415 434-415 TCGGCACCACCATAGCTGAT 199
423 442-423 GCTTGTAGTCGGCACCACCA 200
424 443-424 CGCTTGIAGTCGGCACCACC 201
451 470-451 TATGGGGCATIGACTITCAC 202
452 471-452 GIAIGGGGCATIGACITrC A 203
453 472-453 TGIATGGGGCATTGACTITC 204
-53-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
Target start Target positions siRNA Antisense Strand
SEQ ID NO:
position spanned Sequence ,
454 473-454 TTGIATGGGGCATTGACTTI 205
455 474-455 GTIGTATGGGGCATTGACTT 206
456 475-456 TGTTGTATGGGGCATTGACT 207
457 476-457 TTGTTGTATGGGGCATTGAC 208
458 477-458 TTIGTIGTAIGGGGCATTGA. 209
459 478-459 TTITGTTGTATGGGGCATIG 210
460 479-460 ATITTGTTGTATGGGGCATT 211
461 480-461 GAITTIGTIGTAIGGGGCAT 212
462 481-462 TGAITTTGTIGTATGGGGCA. 213
463 482-463 TTGATTITGITGTAIGGGGC 214
464 483-464 GTTGATITTGTTGTATGGGG 215
473 492-473 AATTCTITGGTIGATTTTGT 216
474 493-474 AAATTCTTTGGITGAITTTG 217
475 494-475 AAAATTCTTTGGTTGATTTT 218
499 518-499 TCAGAGGTGACTGGATCCAC 219
520 539-520 GCCTGACATGTCAGTTCATG 220
564 583-564 GGICACTGCTIGTCCAGATG 221
565 584-565 TGGTCACTGCTTGTCCAGAT 222
566 585-566 ATGGTCACTGCTTGTCCAGA 223
567 586-567 GATGGICACTGCTIGTCCAG 224
641 660-641 CAGTGTGCTGGTCACKITGA 225
642 661-642 TCAGTGTGCTGGIVAC AT-1:G 226
=
643 662-643 C TC AGI'GIGCTGGTCAC Ayr 227
918 937-918 TC"fCCTCCAAATGTGTATCA 228
=
919 938-919 GTCTCCTCCAAATGTGTATC 229
Table 11: CD274 siRNAs ¨ 21rners
Target start Target positions siRNA Antisense Strand SEQ ID
position spanned Sequence NO:
70 90-70
AAAGACAGCAAATA.TCCTCAT 230
_
71 91-71
TAAAGACAGCAAATATCCTCA 231
77. 92-72
ATAAAGACAGCAA.ATATCCTC 232
73 93-73
TATAAAGACAGCAAATATCCT 233
74 94-74
ATATAAAGACAGCAAATA.TCC 234
75 95-75
AATATAAAGACAGCAAATATC 235
-54-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense
Strand SEQ ID
, position spanned Sequence ; NO: ,
76 96-76
GAATATAAAGACAGCAAATAT 236
77 97-77
TGAATATAAAGACAGCAAATA 237
1398 1418-1398
CACAGACTCAAAATAAATAGG 238
1399 1419-1399
TCACAGA.CTCAAAATAAATAG 239
1400 1420-1400
CTCACAGACTCAAAATAAATA 240
1401 1421-1401
CCTCACAGA.CTCAAAATAAAT 241
1402 1422-1402
ACCTCACAGACTCAAAATAAA 242
1403 1423-1403
GACCTCACA.GACTCAAAATAA 243
1404 1424-1404
AGACC'FCACAGACTCAAAATA 244
3038 3058-3038
CAGGGTAGCTA.GCAGICAAGG 245
3240 3260-3240
ITTCITCAGCCITGACAIGTG 246
3241 3261-3241 GTTICTTCA.GCCTTGACA.TGT 247
3242 3262-3242
TGITTCTIVAGCCITGACATG 248
3243 3263-3243 CIGTITCTICAGCCTTGACAT 249
350 370-350
IC'FGAAGIGCAGCATITCCCA 250
351 371-351
ATCTGAAGTGCAGCATTTCCC 251
r
352 372-352
GATCTGAAGTGCAGCATTTCC 252
353 373-353 TGATCTGAAGIGCAGCATTTC 253 .
354 374-354
GTGATCTGAAGTGCAGCA.FTT 254
355 375-355
TGTGAICTGAAGTGCACiCATT 255
------------ 4
415 435-415
GTCGGCACCACCATAGCTGAT 256
423 443-423
CGCTIGTAGTCGCX;ACCACCA , 257
424 444-424
TCGCTTGTAGTCGGCACCACC 258
451 471-451
GTAIGGGGCATTGACTTTCAC 259
452 472-452
TGTATGGGGCATIGACTITCA 260
453 473-453 , TIGTATGGCGCATTGACITTC 261
454 474-454
GTTGTATGGGGCATTGACTTT 262
455 475-455
TGTTGTA.TCiGGGCATTGACTT 263
------------ ---
456 476-456
TTGTTGTATGGGGCATTGACT 264
457 477-457
'FTTGTIGTATGGGGCAITGAC 265
458 478-458 TTTTGTTGTATGGGGCATTGA 266
459 479-459
ATITIGTIGTAIGGGGCAITG 267
460 480-460
GA.TTTTGTTGTA.TGGGGCATT 268
-55-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Target start Target positions siRNA Antisense
Strand SEQ ID
position spanned Sequence NO: ,
461 481-461 TGATITTGTIGTATG(I;GGCAT 269
462 482-462 TTGATTITGTTGTA.TGGGGCA 270
463 483-463 GITGATITTGTIGTATGGGGC 271
464 484-464 GGTTGA.TTTTGTTGTA.TGGGG 272
473 493-473 AAATTCTTIGGTIGATTITGT 273
474 494-474 AAAATICTTTGGTTGAT.TTIG 274
564 584-564 TGGTCACTGCTI-GTCCAGA'FG 275
565 585-565 ATGGTCACTGCTTGTCCA.GAT 276
566 586-566 GAIGGTCAC'FGCTTG'FCCAGA 277
567 587-567 TGATGGICACTGCTTGTCCAG 278
641 661-641 ICAGTGTGC'IGGTCACNITGA 279
642 662-642 CTCA.GTGTGCTGGICACATTG 280
918 938-918 GTCTCCTCCAAATGTGTATCA 281
919 939-919 CGTCTCCTCCAAATGTGTA.TC 282
Example 3: Treatment of cancer using CD274 siRNAs
101211 A human patient presents with a cancer, such as a hepatocellular
carcinoma (HCC). The cancer is a non-metastatic or metastatic cancer. In the
case of HCC,
the patient may also have another liver condition, such as fibrosis,
cirrhosis, non-alcoholic
liver disease, hepatitis, hepatitis B, or hepatitis C. An effective amount of
a CD274 siRNA or
a pharmaceutical composition comprising an effective amount of a CD274 siRNA
is
administered to the patient parenterally. The CD274 siRNA is selected from.
the group
consisting of SEQ ID NOs: 2-380, including any allowed mismatches as described
herein.
The CD274 siRNA can optionally have any of the modifications to individual
nucleobases,
sugars, linkages, nucleosides, or nucleotides as described herein. The CD274
siRNA can also
optionally have a covalently conjugated targeting moiety to improve
selectivity to tumor
and/or liver tissue. The CD274 siRNA can be constructed of deoxyribose sugars
(DNA.
nucleotides), ribose sugars (RNA nucleotides) or any combination thereof The
CD274
siRNA can be constructed of unmodified nucleotides or modified nucleotides or
any
combination thereof. The CD274 siRNA or pharmaceutical composition comprising
the
-56-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
CD274 siRNA can optionally be administered as a combination therapy with
another anti-
neoplastic compound or therapy.
[0122] Following administration of an effective amount of the CD274
siRNA or
the pharmaceutical composition comprising an effective amount of the CD274
siRNA, the
cancer is reduced or eliminated.
Example 4: Treatment of hepatitis B using CD274 siRNAs
[0123] A human patient presents with a hepatitis B infection. The
hepatitis B
infection is acute or chronic. The hepatitis B infection may also be
coincidental with a
hepatitis D infection. The patient may also have another liver conditions,
such as fibrosis,
cirrhosis, non-alcoholic liver disease, or HCC. An effective amount of a CD274
siRNA or a
pharmaceutical composition comprising an effective amount of a CD274 siRNA is
administered to the patient parenterally. The CD274 siRNA is selected from the
group
consisting of SEQ ID NOs: 2-380. The CD274 siRNA can optionally have any of
the
modifications to individual nucleobases, sugars, linkages, nucleosides, or
nucleotides as
described herein, The CD274 siRNA. can also optionally have a covalently
conjugated
targeting moiety to improve selectivity to liver tissue. The CD274 siRNA can
be constructed
of deoxyribose sugars (DNA nucleotides), ribose sugars (RNA nucleotides) or
any
combination thereof The CD274 siRNA can be constructed of unmodified
nucleotides or
modified nucleotides or any combination thereof The CD274 siRNA or
pharmaceutical
composition comprising the CD274 siRNA can optionally be administered as a
combination
therapy with another antiviral medication.
[0124] Following administration of an effective amount of the CD274
siRNA or
the pharmaceutical composition comprising an effective amount of the CD274
siRNA, the
hepatitis B infection (and optionally, hepatitis D infection) is reduced or
eliminated.
Example 5: Treatment of hepatocellular carcinoma cells using siRNAs
[0125] Human hepatocellular carcinoma cells (SNU-387) were seeded at
30,000
cells/well in a 96-well plate. The siRNAs, including any of SEQ ID NOs: 2-380,
were
transfected with Lipofectamine RNAiMax (Life Technologies) in the seeded SNU-
387 cells.
The siRNAs included any of the modifications described herein, including
modification of
-57-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
individual nucleobases, sugars, linkages, nucleosides, or nucleotides. The
modifications of
the siRNAs varied across different sequences. For example, in some sequences,
such as SEQ
ID NOs: 94-167 (19-mers), the sense strand included purines as 2'0Me and
pyrimidines as
2'F, with two nucleotide overhang at the 3'-end, which are two mU nucleotides.
All linkages
in the modified SEQ ID NOs: 94-167 sense strand included phosphodiester (PO)
linkages,
except for the two most 5'- and 3'-end linkages, which were phosphorothioate
(PS), for a
total of four PS linkages. In addition, the antisense strands for SEQ ID NOs:
94-167 and 283-
380 (19-mers) included alternating 2'0Me and 2'F pattern, starting with 2'0Me
at the 5'
end, with two nucleotide overhang at the 3'-end, which are two mU nucleotides.
All linkages
in the modified SEQ ID NOs: 94-167 antisense strand included PO linkages,
except for the
two most 5'- and 3'-end linkages, which were PS linkages, for a total of four
PS linkages.
[0126] As another example, in some sequences, such as in SEQ ID NOs:
283-380
(19-mers), the sense strand included alternating 2'0Me and 2'F pattern,
starting with 2'F at
the 5' end, with two nucleotide overhang at the 3'-end, which are two mU
nucleotides. All
linkages in the modified SEQ ID NOs: 283-380 sense strand included
phosphodiester (PO)
linkages, except for the two most 5'- and 3'-end linkages, which were
phosphorothioate (PS),
for a total of four PS linkages. In addition, the antisense strands for SEQ ID
NOs: 283-380
(19-mers) included alternating 2'0Me and 2'F pattern, starting with 2'0Me at
the 5' end,
with two nucleotide overhang at the 3'-end, which are two mU nucleotides. All
linkages in
the modified SEQ ID NOs: 283-380 antisense strand included PO linkages, except
for the
two most 5% and 3'-end linkages, which were PS linkages, for a total of four
PS linkages.
[0127] As another example, in some sequences, such as in SEQ ID NOs:
230-282
(21-mers), the sense strand included purines as 2'0Me and pyrimidines as 2'F,
with all
linkages as PO, except for the two most 5'-end linkages, which were PS
linkages, for a total
of two PS linkages. The sense strand in these 21-mer sequences did not include
an overhang,
but were blunt ended. The antisense strand for SEQ ID NOs: 230-282 (21-mers)
included
alternating 2'0Me and 2'F pattern, starting with 2'0Me at the 5'end, with a
two nucleotide
overhang at the 3'-end, which were two mU nucleotides. All linkages in the 21-
mer antisense
strands were PO linkages, except for the two most 5'- and 3'-end linkages,
which were PS
linkages, for a total of four PS linkages. It is to be understood that these
modifications to
-58-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
these sequences are exemplary, and that any modifications as described herein
on any siRNA
sequence can be employed.
[0128] For dose response curves, a 4-fold dilution series of siRNA (top
dose 50
nM; 6 concentrations tested total) was tested. At 48 hr post transfection,
cells were harvested,
RNA was extracted with F.Neasy 96 Kits (Qiagen), and RT-qPCR is performed to
assess PD-
Li gene knockdown. Cell viability (of separate plate treated the same way) was
assessed at
48 h post transfection using Cell Titer (310 (Promega); protocol according to
manufacturer's
instructions. Data was fit with GraphPad Prism using a four parameter close
response
equation. Table 12 provides representative EC50 and CC50 values for selected
siRNA.
Figure 1 depicts the fraction of PD-L1 mRNA remaining.
Table 12: Relative Gene Expression for select siRNA sequences
SEQ ID NO: .EC50 (nN1) CC50 (gal)
106 A X
125 c X
134 B X
127 C X
A <04 nM; B = 04-0.8 LIM; C > 0.8-1.2 n11/1
X> 50 nM; Y < 50 nM
[0129] In a separate experiment, the siRNA were transfected with
Lipofectamine
RNAiMa.x (Life Technologies) in SN12-387 cells, seeded at 30,000 cells/well in
96-well
plates. Two concentrations were tested (20 and 0.2 nM) for each siRNA. At 48
hr post
transfection, cells were harvested, RNA was extracted with R_Neasy 96 Kits
(Qiagen), and
RT-qPCR, was performed to assess PD-1-1 gene knockdown. Cell viability (of
separate plate
treated the same way) was assessed at 48 h post transfection using Cell Titer
Cilo (Promega);
protocol according to manufacturer's instructions. Results are shown in Table
13; specific
modifications of the siRNA.s are indicated in the table, which are the
modifications as
described herein in Example 5.
-59-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
Table 13: Percent Reduction of PD-L1 Gene with select siRNAs
% Reduction of PD- % Reduction of PD-
SEQ ID NO: CC50 (nM)
Li gene at 50 nM Li gene at 1. nM
19-mers (modification pattern as described above in Example 5)
, --
137 D C X
138 D D X
105 D D X
106 C A X
125 B C X
¨
128 C D X
129 D C X
130 D D X
. __________________________________________________________________ .
135 C C X
136 D D X
__________ .......___ ¨
139 D C X
152 C C X
158 D D X
. __________________________________________________________________ .
159 D D X
104 C C X
107 C C X
108 D C X
94 C D X
. __________________________________________________________________ .
95 C C X
102 D D X
103 B B X
133 A B X
134 A C X
140 B C X
141 C C X
; 147 C C X
i 148 D C X
149 C D X
_________________________________________________ ....._ .......
153 C D X
156 D D X
-60-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
157 D D X
160 D D X
165 D D X
, ________________________________________________________________
167 D D X
109 D D X
119 ' D D X
120 D D X
, ________________________________________________________________
121 D D X
, ________________________________________________________________
126 B C X
127 B D X
19-mers (modification pattern as described above in Example 5)
283 D D X
,
284 D D X
285 C D X
286 C D X
287 D D X
288 C D X
, ________________________________________________________________
289 D D X
290 D D X
291 C D X
292 C D X
293 D D X
, ________________________________________________________________
294 D D X
295 D D X
7.96 D D X
297 C D X
,
298 C D X
, ________________________________________________________________
299 C D X
300 B D X
301 B D X
302 D D X
,
303 B D X
304 D D X
305 B D X
-61-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
306 D D X
307 B D X
308 D D X
,
309 B D X
310 , C D X
311 D D X
312 B C X
,
313 C D X
,
314 B C X
315 , C C X
317 C D X
318 B D X
,
319 C D X
320 B C X
321 , B D X
322 B D X
323 C D X
,
324 B C X
325 C D X
326 D D X
327 C D X
328 C D X
,
329 C D X
330 D D X
331 B C X
332 C D X
,
333 C D X
,
334 D D X
335 C D X
336 B C X
337 B C X
,
338 D D X
339 , B C X
340 C D X
-62-
CA 03172823 2022-08-24
WO 2021/173811
PCT/US2021/019628
341 D D X
342 B D X
343 B D X
, ________________________________________________________________
344 D D X
345 D D X
346 C D X
347 D D X
, ________________________________________________________________
348 C D X
, ________________________________________________________________
349 D D X
350 C D X
351 D D X
352 B D X
,
354 D D X
373 B C X
374 C C X
375 C C X
376 C D X
, ________________________________________________________________
377 C C X
378 C C X
379 D D X
380 C D X
21- Tiers (modification pattern as described above in Example 5)
230 B C X
237 A B X
252 D D X
253 D D X
, ________________________________________________________________
254 D D X
, ________________________________________________________________
2.55 D D X
256 D D X
257 D D X
258 D C X
, ________________________________________________________________
259 D D X
260 D D X
261 D D X
-63-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
262 B D X
263 A. C X
264 B D X
270 B D X
271 B C X
272 C D X
275 C B X
276 C D X
277 D D X
278 D D X
282 B D X
238 B D X
239 C D X
240 D D X
241 D D X
242 D D X
243 C D X
_________________________________________________________________ =
246 C C X
247 C D X
248 D D X
A> 75%-100%; B> 50%-75%; C> 25%-50%; D = 0%-25%
X> 20 nM;Y<20 nM
Example 6: In vivo treatment of Mice with siRNA
[0130] C57BL/6 mice were provided. One subcutaneous dose of 7.5 mg/kg
siRNA or vehicle (phosphate buffered saline) was administered in mice (n...4
per group) on
day 0. The siRNA included any of SEQ ID NOs: 2-380, including any modification
described herein. On day 3, 10 mg/kg low molecular weight polyi:C (LMW PIC,
from
Invivogen) was dosed by IV to all groups. Mice were sacrificed 5 hours post-
LMW PIC
dose. Liver was sectioned and placed in RNALater (Qiagen) for RNA extraction.
RNA was
extracted from liver samples and PD-L1 gene expression was measured by RT-
qPCR. P
values were determined from a t-test comparing treatment groups to vehicle
control. The
values are provided in Figure 2, and in Table 14.
-64-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
Table 14: Relative Gene Expression for select siRNA sequences
SE P value
(t-test)
Q ID
Modification Relative Gene Expression
Compared to Vehicle
NO:
7 Group
Vehicle 1.01
106 3'GalNac4
0.61 0.029
on S strand
134 3'Cia1Nac4
0.54 0.027
on S strand
106 5'VP on AS
strand
0.44 0.002
3 'GalNac4
on S strand
134 5'VP on AS
strand
0.8 0.002
3 'GalNac4 3
on S strand
[0131] The
sequences including the modifications for each of the siRNAs as set
forth in Table 14 are provided below in Table 15:
Table 15: Sequence modifications for sense strand and antisense strand of
siRNAs of Table
14
SEQ ID
NO: Sequence (5 to 3')
106 S strand:
fUpsmApsfUfUfUmMUfUflifUmGmArnGfUfCfUmGfUmG-
GaINAc4
AS strand:
mCpsfApsmCfAmGfAmCfUmCfAmAfAmAfUmAfAmAfUmApsmUpsmU
134 5 strand: fUpsmGpsmGfUmGmGfUmGfCfCmGmAfCfUmAfCmAmAmG-
GaINAc4
AS strand:
mCpsflipsmUfGmUfAmGftimCfGinGfCmAfCmCfAmCfCmApsmUpsmU
106 S strand:
fljpsmApsfUfUftJmAfUfaUfUmGmAmGfUfCfUmGfUmG-
GaINAc4
AS strand:
VPmCpsfApsmCfAmGfAmCfUmCfAmAfAmAfUmAfAmAftimApsmUpsmt.1
134 S strand: fUpsmGpsmGfUmGmGfUmGfCfCmGmAfCfUmAfCmAmArriG-
GaINA.c4
AS strand:
VPmCpsfUpsmUfGmUfAmGfUmCfGrriGfCmAfCmCfAmCfCmApsmUpsmli
-65-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0132] The example siRNAs, including the example sequences and example
modifications as described in the examples, are intended as exemplary
sequences and
modifications. However, it is to be understood that the disclosure relates to
any siRNA
sequence as set forth herein, having any modification or combination of
modifications as set
forth herein may be implemented in the examples.
[0133! In at least some of the previously described embodiments, one or
more
elements used in an embodiment can interchangeably be used in another
embodiment unless
such a replacement is not technically feasible. It will be appreciated by
those skilled in the art
that various other omissions, additions and modifications may be made to the
methods and
structures described above without departing from the scope of the claimed
subject matter.
All such modifications and changes are intended to fall within the scope of
the subject
matter, as defined by the appended claims.
[01341 With respect to the use of substantially any plural and/or
singular terms
herein, those having skill in the art can translate from the plural to the
singular and/or from
the singular to the plural as is appropriate to the context and/or
application. The various
singular/plural permutations may be expressly set forth herein for sake of
clarity.
[0135] It will be understood by those within the art that, in general,
terms used
herein, and especially in the appended claims (e.g., bodies of the appended
claims) are
generally intended as "open." terms (e.g., the term. "including" should be
interpreted as
"including but not limited to," the term "having" should be interpreted as
"having at least,"
the term "includes" should be interpreted as "includes but is not limited to,"
etc.). It will be
further understood by those within the art that if a specific number of an
introduced claim
recitation is intended, such an intent will be explicitly recited in the
claim, and in the absence
of such recitation no such intent is present. For example, as an aid to
understanding, the
following appended claims may contain usage of the introductory phrases "at
least one" and
"one or more" to introduce claim recitations. However, the use of such phrases
should not be
construed to imply that the introduction of a claim recitation by the
indefinite articles "a" or
"an" limits any particular claim containing such introduced claim recitation
to embodiments
containing only one such recitation, even when the same claim includes the
introductory
phrases "one or more" or "at least one" and indefinite articles such as "a" or
"an" (e.g., "a"
and/or "an" should be interpreted to mean "at least one" or "one or more");
the same holds
-66-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
true for the use of definite articles used to introduce claim recitations. In
addition, even if a
specific number of an introduced claim recitation is explicitly recited, those
skilled in the art
will recognize that such recitation should be interpreted to mean at least the
recited number
(e.g., the bare recitation of "two recitations," without other modifiers,
means at least two
recitations, or two or more recitations). Furthermore, in those instances
where a convention
analogous to "at least one of A, B, and C, etc." is used, in general such a
construction is
intended in the sense one having skill in the art would understand the
convention (e.g., "a
system having at least one of A, B, and C" would include but not be limited to
systems that
have A alone, B alone, C alone, A and B together, A and C together, B and C
together,
and/or A, B, and C together, etc.). In those instances where a convention
analogous to "at
least one of A, B, or C, etc." is used, in general such a construction is
intended in the sense
one having skill in the art would understand the convention (e.g., " a system
having at least
one of A, B, or C" would include but not be limited to systems that have A
alone, B alone, C
alone, A and B together, A and C together, B and C together, and/or A, B, and
C together,
etc.). It will be further understood by those within the art that virtually
any disjunctive word
and/or phrase presenting two or more alternative terms, whether in the
description or claims,
should be understood to contemplate the possibilities of including one of the
terms, either of
the terms, or both terms. For example, the phrase "A or B" will be understood
to include the
possibilities of "A." or "B" or "A and B."
[0136] In addition, where features or aspects of the disclosure are
described in
term.s of Markush groups, those skilled in the art will recognize that the
disclosure is also
thereby described in terms of any individual member or subgroup of members of
the
Markush group.
[0137] As will be understood by one skilled in the art, for any and all
purposes,
such as in terms of providing a written description, all ranges disclosed
herein also
encompass any and all possible sub-ranges and combinations of sub-ranges
thereof. Any
listed range can be easily recognized as sufficiently describing and enabling
the same range
being broken down into at least equal halves, thirds, quarters, fifths,
tenths, etc. As a non-
limiting example, each range discussed herein can be readily broken down into
a lower third,
middle third and upper third, etc. As will also be understood by one skilled
in the art all
language such as "up to," "at least," "greater than," "less than," and the
like include the
-67-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
number recited and refer to ranges which can be subsequently broken down into
sub-ranges
as discussed above. Finally, as will be understood by one skilled in the art,
a range includes
each individual member. Thus, for example, a group having 1-3 articles refers
to groups
having 1, 2, or 3 articles. Similarly, a group having 1-5 articles refers to
groups having 1, 2,
3, 4, or 5 articles, and so forth.
[0138[ While various aspects and embodiments have been disclosed
herein, other
aspects and embodiments will be apparent to those skilled in the art. The
various aspects and
embodiments disclosed herein are for purposes of illustration and are not
intended to be
limiting, with the true scope and spirit being indicated by the following
claims.
[0139j All references cited herein, including but not limited to
published and
unpublished applications, patents, and literature references, are incorporated
herein by
reference in their entirety and are hereby made a part of this specification.
To the extent
publications and patents or patent applications incorporated by reference
contradict the
disclosure contained in the specification, the specification is intended to
supersede and/or
take precedence over any such contradictory material.
References
[0140] 1, U.S. 2017/0283496
[0141] 2. Akinleye, .A & Rasool Z. Immune Checkpoint Inhibitors of Pa-
Li as
Cancer Therapeutics. J. Hematol. Oncol. (2019) 12(1):92.
[0142] 3. Wu, Y et al. PD-L1 Distribution and Perspective for Cancer
hnmunotherapy --- Blockade, Knockdown., or Inhibition. Front. immunol. (2019)
10:2022.
[0143] 4. Sun., C et al. Regulation and Function of the PD-4.1
Checkpoint.
Immunity. (2018) 48(3):434-452.
[0144] 5. Schonrich, G & Raferty MI, The PD-1/13D-L1 Axis and Virus
Infections: A Delicate Balance. Front. Cell. Infect. Microbiol. (2019) 9:207
[0145! 6. Ostergaard, ME et al. Fluorinated Nucleotide Modifications
Modulate
Allele Selectivity of SNP-Targeting Antisense Oligonucleotides. Ther,
.Nucleic Acids.
(2017) 7:20-30.
[0146] 7. Di Fusco, D et al. Antisense Oligonucleotide: Basic Concepts
and
Therapeutic Application in Inflammatory Bowel Disease. Front Pharmaca (2019)
10:305.
-68-
CA 03172823 2022-08-24
WO 2021/173811 PCT/US2021/019628
[0147] 8. Wurster, CD & Ludolph AC. Antisense Oligonucleotides in
Neurological Disorders. Ther. Adv. Neurol. Disord. (2018) 11:1-19.
[0148] 9. Balsitis S et al. Safety and Efficacy of Anti-PD-L1 Therapy
in the
Woodchuck Model of HMI Infection. (2018) 13(2):1-23.
[0149] Although the foregoing has been described in some detail by way
of
illustrations and examples for purposes of clarity and understanding, it will
be understood by
those of skill in the art that numerous and various modifications can be made
without
departing from the spirit of the present disclosure. Therefore, it should be
clearly understood
that the forms disclosed herein are illustrative only and are not intended to
limit the scope of
the present disclosure, but rather to also cover all modification and
alternatives coming with
the true scope and spirit of the invention.
-69-
